"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)",1,EHR,IntermediateOutcome,Y,92.62 - 74.49,74.48 - 59.10,59.09 - 46.87,46.86 - 37.91,37.9 - 31.42,31.41 - 26.06,26.05 - 20.94,<= 20.93,No
"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)",1,Registry/QCDR,IntermediateOutcome,Y,90.32 - 71.44,71.43 - 56.83,56.82 - 42.68,42.67 - 32.52,32.51 - 24.82,24.81 - 19.01,19.0 - 13.34,<= 13.33,No
"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)",1,Claims,IntermediateOutcome,Y,45.64 - 26.93,26.92 - 18.76,18.75 - 14.76,14.75 - 11.68,11.67 - 9.10,9.09 - 7.01,7.0 - 4.56,<= 4.55,No
"Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)",5,Registry/QCDR,Process,Y,68.52 - 78.88,78.87 - 84.76,84.75 - 90.17,90.16 - 94.37,94.36 - 97.38,97.37 - 99.37,99.36 - 99.99,100.00,No
"Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)",5,EHR,Process,Y,59.55 - 68.98,68.97 - 74.01,74.0 - 77.28,77.27 - 80.49,80.48 - 83.34,83.33 - 86.47,86.46 - 90.01,<= 90.0,No
"Coronary Artery Disease (CAD): Antiplatelet Therapy",6,Registry/QCDR,Process,Y,74.76 - 83.38,83.37 - 88.25,88.24 - 91.31,91.3 - 93.76,93.75 - 95.72,95.71 - 97.57,97.56 - 99.99,100.00,No
"Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)",7,EHR,Process,Y,70.76 - 78.14,78.13 - 81.83,81.82 - 84.63,84.62 - 86.75,86.74 - 88.72,88.71 - 90.61,90.6 - 92.60,<= 92.59,No
"Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)",7,Registry/QCDR,Process,Y,82.76 - 87.97,87.96 - 90.38,90.37 - 92.60,92.59 - 94.21,94.2 - 95.53,95.52 - 96.98,96.97 - 98.58,<= 98.57,No
"Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)",8,EHR,Process,Y,70.0 - 79.00,78.99 - 83.88,83.87 - 87.19,87.18 - 89.56,89.55 - 91.54,91.53 - 93.49,93.48 - 95.25,<= 95.24,No
"Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)",8,Registry/QCDR,Process,Y,85.71 - 91.31,91.3 - 94.45,94.44 - 95.84,95.83 - 97.26,97.25 - 98.45,98.44 - 99.99,--,100.00,No
"Anti-Depressant Medication Management",9,EHR,Process,Y,18.25 - 28.45,28.44 - 37.05,37.04 - 44.09,44.08 - 49.37,49.36 - 53.31,53.3 - 59.79,59.78 - 77.69,<= 77.68,No
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation",012,Registry/QCDR,Process,Y,84.42 - 94.59,94.58 - 98.33,98.32 - 99.53,99.52 - 99.99,--,--,--,100.00,Yes
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation",012,EHR,Process,Y,66.67 - 81.26,81.25 - 87.21,87.2 - 91.08,91.07 - 93.93,93.92 - 95.91,95.9 - 97.66,97.65 - 98.81,<= 98.8,Yes
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation",012,Claims,Process,Y,97.37 - 99.99,--,--,--,--,--,--,100.00,Yes
"Age-Related Macular Degeneration (AMD): Dilated Macular Examination",014,Registry/QCDR,Process,Y,60.77 - 81.86,81.85 - 90.33,90.32 - 94.43,94.42 - 96.94,96.93 - 98.60,98.59 - 99.63,99.62 - 99.99,100.00,Yes
"Age-Related Macular Degeneration (AMD): Dilated Macular Examination",014,Claims,Process,Y,92.31 - 99.99,--,--,--,--,--,--,100.00,Yes
"Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy",018,EHR,Process,Y,53.46 - 73.60,73.59 - 83.49,83.48 - 89.30,89.29 - 93.26,93.25 - 95.71,95.7 - 97.51,97.5 - 98.92,<= 98.91,No
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care",019,Claims,Process,Y,99.35 - 99.99,--,--,--,--,--,--,100.00,Yes
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care",019,Registry/QCDR,Process,Y,38.78 - 74.20,74.19 - 87.63,87.62 - 93.89,93.88 - 98.66,98.65 - 99.99,--,--,100.00,Yes
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care",019,EHR,Process,Y,35.5 - 58.51,58.5 - 71.08,71.07 - 80.16,80.15 - 86.52,86.51 - 91.35,91.34 - 95.25,95.24 - 98.02,<= 98.01,Yes
"Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second-Generation Cephalosporin",021,Registry/QCDR,Process,Y,56.88 - 94.35,94.34 - 98.99,98.98 - 99.99,--,--,--,--,100.00,Yes
"Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second-Generation Cephalosporin",021,Claims,Process,Y,94.59 - 99.99,--,--,--,--,--,--,100.00,Yes
"Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)",023,Claims,Process,Y,98.39 - 99.99,--,--,--,--,--,--,100.00,Yes
"Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)",023,Registry/QCDR,Process,Y,79.67 - 96.07,96.06 - 99.42,99.41 - 99.99,--,--,--,--,100.00,Yes
"Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older",024,Registry/QCDR,Process,Y,12.29 - 25.04,25.03 - 52.81,52.8 - 69.08,69.07 - 76.98,76.97 - 87.89,87.88 - 95.85,95.84 - 99.95,<= 99.94,Yes
"Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older",024,Claims,Process,Y,54.84 - 87.11,87.1 - 95.93,95.92 - 97.31,97.3 - 99.36,99.35 - 99.99,--,--,100.00,Yes
"Screening for Osteoporosis for Women Aged 65-85 Years of Age",039,Registry/QCDR,Process,Y,2.93 - 10.72,10.71 - 22.42,22.41 - 34.66,34.65 - 48.67,48.66 - 60.64,60.63 - 72.83,72.82 - 82.53,<= 82.52,No
"Screening for Osteoporosis for Women Aged 65-85 Years of Age",039,Claims,Process,Y,23.81 - 37.71,37.7 - 45.01,45.0 - 51.66,51.65 - 56.99,56.98 - 63.42,63.41 - 70.70,70.69 - 80.01,<= 80.0,No
"Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery",043,Registry/QCDR,Process,Y,97.62 - 98.83,98.82 - 99.99,--,--,--,--,--,100.00,Yes
"Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery",044,Registry/QCDR,Process,Y,91.4 - 96.68,96.67 - 98.07,98.06 - 99.10,99.09 - 99.99,--,--,--,100.00,Yes
"Medication Reconciliation Post-Discharge",046,Registry/QCDR,Process,Y,92.22 - 97.63,97.62 - 99.54,99.53 - 99.99,--,--,--,--,100.00,Yes
"Medication Reconciliation Post-Discharge",046,Claims,Process,Y,96.0 - 99.99,--,--,--,--,--,--,100.00,Yes
"Advance Care Plan",047,Registry/QCDR,Process,Y,4.09 - 23.37,23.36 - 49.25,49.24 - 68.22,68.21 - 82.85,82.84 - 91.55,91.54 - 96.71,96.7 - 99.41,<= 99.4,Yes
"Advance Care Plan",047,Claims,Process,Y,18.18 - 51.75,51.74 - 86.66,86.65 - 95.44,95.43 - 98.75,98.74 - 99.68,99.67 - 99.99,--,100.00,Yes
"Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older",048,Claims,Process,Y,1.3 - 3.29,3.28 - 7.48,7.47 - 83.25,83.24 - 98.43,98.42 - 99.99,--,--,100.00,Yes
"Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older",048,Registry/QCDR,Process,Y,4.2 - 19.07,19.06 - 42.43,42.42 - 63.14,63.13 - 79.27,79.26 - 92.96,92.95 - 97.45,97.44 - 99.75,<= 99.74,Yes
"Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older",050,Claims,Process,Y,64.52 - 95.25,95.24 - 98.99,98.98 - 99.99,--,--,--,--,100.00,Yes
"Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older",050,Registry/QCDR,Process,Y,25.58 - 46.16,46.15 - 59.10,59.09 - 70.98,70.97 - 79.18,79.17 - 87.69,87.68 - 94.04,94.03 - 99.18,<= 99.17,Yes
"Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation",051,Claims,Process,Y,9.76 - 26.18,26.17 - 55.01,55.0 - 80.30,80.29 - 95.30,95.29 - 99.99,--,--,100.00,Yes
"Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation",051,Registry/QCDR,Process,Y,17.16 - 34.19,34.18 - 50.69,50.68 - 66.27,66.26 - 76.88,76.87 - 85.21,85.2 - 93.88,93.87 - 98.75,<= 98.74,Yes
"Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy",052,Claims,Process,Y,92.59 - 99.54,99.53 - 99.99,--,--,--,--,--,100.00,Yes
"Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy",052,Registry/QCDR,Process,Y,62.5 - 73.34,73.33 - 83.94,83.93 - 90.07,90.06 - 97.51,97.5 - 99.99,--,--,100.00,Yes
"Appropriate Treatment for Children with Upper Respiratory Infection (URI)",065,EHR,Process,Y,75.95 - 84.75,84.74 - 88.65,88.64 - 91.54,91.53 - 93.42,93.41 - 95.00,94.99 - 96.40,96.39 - 97.94,<= 97.93,No
"Appropriate Treatment for Children with Upper Respiratory Infection (URI)",065,Registry/QCDR,Process,Y,89.05 - 93.41,93.4 - 95.91,95.9 - 97.75,97.74 - 98.73,98.72 - 99.47,99.46 - 99.99,--,100.00,No
"Appropriate Testing for Children with Pharyngitis",066,EHR,Process,Y,17.35 - 45.23,45.22 - 59.90,59.89 - 68.94,68.93 - 77.06,77.05 - 81.27,81.26 - 85.26,85.25 - 89.57,<= 89.56,No
"Appropriate Testing for Children with Pharyngitis",066,Registry/QCDR,Process,Y,56.0 - 65.89,65.88 - 72.86,72.85 - 77.79,77.78 - 81.99,81.98 - 85.72,85.71 - 89.30,89.29 - 92.73,<= 92.72,No
"Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow",067,Registry/QCDR,Process,Y,8.33 - 17.66,17.65 - 24.33,24.32 - 31.83,31.82 - 47.51,47.5 - 70.01,70.0 - 98.61,98.6 - 99.99,100.00,No
"Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry",070,Registry/QCDR,Process,Y,6.98 - 8.90,8.89 - 17.66,17.65 - 32.27,32.26 - 45.46,45.45 - 68.76,68.75 - 80.01,80.0 - 99.99,100.00,No
"Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections",076,Registry/QCDR,Process,Y,89.59 - 96.56,96.55 - 98.76,98.75 - 99.90,99.89 - 99.99,--,--,--,100.00,Yes
"Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections",076,Claims,Process,Y,91.84 - 98.79,98.78 - 99.99,--,--,--,--,--,100.00,Yes
"Acute Otitis Externa (AOE): Topical Therapy",091,Claims,Process,Y,32.14 - 54.01,54.0 - 80.50,80.49 - 94.75,94.74 - 98.36,98.35 - 99.99,--,--,100.00,Yes
"Acute Otitis Externa (AOE): Topical Therapy",091,Registry/QCDR,Process,Y,58.16 - 75.01,75.0 - 83.79,83.78 - 88.72,88.71 - 92.85,92.84 - 95.71,95.7 - 98.40,98.39 - 99.99,100.00,Yes
"Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use",093,Claims,Process,Y,93.1 - 99.99,--,--,--,--,--,--,100.00,Yes
"Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use",093,Registry/QCDR,Process,Y,73.91 - 83.75,83.74 - 90.01,90.0 - 93.44,93.43 - 95.84,95.83 - 97.74,97.73 - 99.67,99.66 - 99.99,100.00,Yes
"Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade",099,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade",099,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade",100,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade",100,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients",102,Registry/QCDR,Process,Y,88.89 - 99.99,--,--,--,--,--,--,100.00,No
"Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer",104,Registry/QCDR,Process,Y,54.29 - 82.36,82.35 - 95.67,95.66 - 97.40,97.39 - 98.49,98.48 - 99.99,--,--,100.00,No
"Adult Major Depressive Disorder (MDD): Suicide Risk Assessment",107,EHR,Process,Y,0.75 - 2.61,2.6 - 8.01,8.0 - 17.15,17.14 - 30.32,30.31 - 43.79,43.78 - 59.02,59.01 - 82.77,<= 82.76,No
"Osteoarthritis (OA): Function and Pain Assessment",109,Registry/QCDR,Process,Y,3.21 - 19.18,19.17 - 36.14,36.13 - 58.47,58.46 - 85.47,85.46 - 97.13,97.12 - 99.99,--,100.00,Yes
"Osteoarthritis (OA): Function and Pain Assessment",109,Claims,Process,Y,76.8 - 96.44,96.43 - 98.68,98.67 - 99.78,99.77 - 99.99,--,--,--,100.00,Yes
"Preventive Care and Screening: Influenza Immunization",110,EHR,Process,Y,3.35 - 12.69,12.68 - 21.30,21.29 - 29.14,29.13 - 36.51,36.5 - 44.64,44.63 - 53.19,53.18 - 65.00,<= 64.99,No
"Preventive Care and Screening: Influenza Immunization",110,Claims,Process,Y,16.13 - 28.58,28.57 - 41.58,41.57 - 56.71,56.7 - 72.85,72.84 - 84.83,84.82 - 96.33,96.32 - 99.99,100.00,No
"Preventive Care and Screening: Influenza Immunization",110,Registry/QCDR,Process,Y,11.37 - 26.25,26.24 - 39.29,39.28 - 51.28,51.27 - 61.66,61.65 - 71.14,71.13 - 81.99,81.98 - 92.95,<= 92.94,No
"Pneumococcal Vaccination Status for Older Adults",111,Registry/QCDR,Process,Y,13.71 - 34.33,34.32 - 50.69,50.68 - 61.26,61.25 - 68.82,68.81 - 74.46,74.45 - 79.62,79.61 - 84.89,<= 84.88,No
"Pneumococcal Vaccination Status for Older Adults",111,EHR,Process,Y,4.44 - 17.25,17.24 - 29.92,29.91 - 41.79,41.78 - 52.08,52.07 - 61.85,61.84 - 70.82,70.81 - 79.40,<= 79.39,No
"Pneumococcal Vaccination Status for Older Adults",111,Claims,Process,Y,40.71 - 56.53,56.52 - 66.16,66.15 - 74.44,74.43 - 81.13,81.12 - 86.31,86.3 - 92.36,92.35 - 98.12,<= 98.11,No
"Breast Cancer Screening",112,Claims,Process,Y,28.57 - 51.23,51.22 - 61.60,61.59 - 68.61,68.6 - 75.96,75.95 - 83.79,83.78 - 91.95,91.94 - 98.52,<= 98.51,No
"Breast Cancer Screening",112,Registry/QCDR,Process,Y,7.44 - 19.80,19.79 - 34.30,34.29 - 47.50,47.49 - 55.72,55.71 - 64.21,64.2 - 73.41,73.4 - 82.18,<= 82.17,No
"Breast Cancer Screening",112,EHR,Process,Y,7.32 - 20.79,20.78 - 33.34,33.33 - 43.19,43.18 - 51.57,51.56 - 58.99,58.98 - 65.82,65.81 - 72.88,<= 72.87,No
"Colorectal Cancer Screening",113,EHR,Process,Y,2.6 - 13.00,12.99 - 25.27,25.26 - 35.56,35.55 - 45.66,45.65 - 55.55,55.54 - 65.15,65.14 - 74.49,<= 74.48,No
"Colorectal Cancer Screening",113,Registry/QCDR,Process,Y,4.56 - 17.05,17.04 - 31.82,31.81 - 47.70,47.69 - 59.77,59.76 - 68.62,68.61 - 78.23,78.22 - 87.31,<= 87.3,No
"Colorectal Cancer Screening",113,Claims,Process,Y,23.8 - 37.31,37.3 - 51.15,51.14 - 64.08,64.07 - 76.91,76.9 - 86.99,86.98 - 93.97,93.96 - 99.25,<= 99.24,No
"Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis",116,Registry/QCDR,Process,Y,37.5 - 48.36,48.35 - 60.75,60.74 - 71.31,71.3 - 81.51,81.5 - 91.68,91.67 - 97.84,97.83 - 99.63,<= 99.62,No
"Diabetes: Eye Exam",117,EHR,Process,Y,6.84 - 16.68,16.67 - 25.94,25.93 - 36.06,36.05 - 50.01,50.0 - 75.27,75.26 - 95.32,95.31 - 98.56,<= 98.55,Yes
"Diabetes: Eye Exam",117,Claims,Process,Y,25.78 - 79.36,79.35 - 96.52,96.51 - 99.99,--,--,--,--,100.00,Yes
"Diabetes: Eye Exam",117,Registry/QCDR,Process,Y,23.19 - 64.07,64.06 - 89.08,89.07 - 95.51,95.5 - 97.86,97.85 - 99.39,99.38 - 99.99,--,100.00,Yes
"Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)",118,Registry/QCDR,Process,Y,71.43 - 77.06,77.05 - 79.66,79.65 - 81.95,81.94 - 84.13,84.12 - 85.72,85.71 - 88.47,88.46 - 91.44,<= 91.43,No
"Diabetes: Medical Attention for Nephropathy",119,EHR,Process,Y,53.57 - 67.33,67.32 - 74.37,74.36 - 79.32,79.31 - 83.48,83.47 - 87.05,87.04 - 90.30,90.29 - 93.95,<= 93.94,No
"Diabetes: Medical Attention for Nephropathy",119,Registry/QCDR,Process,Y,57.77 - 72.74,72.73 - 79.81,79.8 - 83.78,83.77 - 87.35,87.34 - 90.44,90.43 - 96.24,96.23 - 99.57,<= 99.56,No
"Adult Kidney Disease: Blood Pressure Management",122,Registry/QCDR,IntermediateOutcome,Y,55.21 - 71.00,70.99 - 82.73,82.72 - 92.26,92.25 - 95.76,95.75 - 97.68,97.67 - 98.78,98.77 - 99.68,<= 99.67,No
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,Registry/QCDR,Process,Y,26.73 - 54.47,54.46 - 74.22,74.21 - 84.73,84.72 - 91.71,91.7 - 97.23,97.22 - 99.76,99.75 - 99.99,100.00,Yes
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,Registry/QCDR,Process,Y,22.52 - 49.08,49.07 - 69.53,69.52 - 81.49,81.48 - 89.94,89.93 - 97.09,97.08 - 99.66,99.65 - 99.99,100.00,Yes
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan",128,EHR,Process,Y,17.49 - 22.07,22.06 - 26.00,25.99 - 30.69,30.68 - 37.41,37.4 - 48.74,48.73 - 65.41,65.4 - 81.95,<= 81.94,Yes
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan",128,Claims,Process,Y,32.59 - 49.66,49.65 - 78.24,78.23 - 93.91,93.9 - 99.10,99.09 - 99.99,--,--,100.00,Yes
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan",128,Registry/QCDR,Process,Y,22.92 - 33.87,33.86 - 52.42,52.41 - 70.23,70.22 - 83.87,83.86 - 92.31,92.3 - 97.04,97.03 - 99.28,<= 99.27,Yes
"Documentation of Current Medications in the Medical Record",130,EHR,Process,Y,66.02 - 84.86,84.85 - 91.70,91.69 - 95.20,95.19 - 97.37,97.36 - 98.72,98.71 - 99.48,99.47 - 99.86,<= 99.85,Yes
"Documentation of Current Medications in the Medical Record",130,Registry/QCDR,Process,Y,43.64 - 88.90,88.89 - 97.20,97.19 - 99.10,99.09 - 99.70,99.69 - 99.93,99.92 - 99.99,--,100.00,Yes
"Documentation of Current Medications in the Medical Record",130,Claims,Process,Y,93.39 - 98.66,98.65 - 99.70,99.69 - 99.99,--,--,--,--,100.00,Yes
"Pain Assessment and Follow-Up",131,Claims,Process,Y,68.35 - 96.59,96.58 - 99.58,99.57 - 99.99,--,--,--,--,100.00,Yes
"Pain Assessment and Follow-Up",131,Registry/QCDR,Process,Y,1.25 - 15.68,15.67 - 39.11,39.1 - 67.05,67.04 - 85.47,85.46 - 94.59,94.58 - 98.89,98.88 - 99.99,100.00,Yes
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan",134,Claims,Process,Y,0.89 - 20.73,20.72 - 64.86,64.85 - 90.23,90.22 - 99.56,99.55 - 99.99,--,--,100.00,Yes
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan",134,Registry/QCDR,Process,Y,2.82 - 16.98,16.97 - 38.32,38.31 - 61.26,61.25 - 74.41,74.4 - 85.00,84.99 - 93.15,93.14 - 98.40,<= 98.39,Yes
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan",134,EHR,Process,Y,1.83 - 5.67,5.66 - 10.75,10.74 - 16.74,16.73 - 26.76,26.75 - 40.49,40.48 - 56.32,56.31 - 73.26,<= 73.25,Yes
"Melanoma: Continuity of Care - Recall System",137,Registry/QCDR,Structure,Y,67.24 - 91.03,91.02 - 97.67,97.66 - 99.99,--,--,--,--,100.00,No
"Melanoma: Coordination of Care",138,Registry/QCDR,Process,Y,25.49 - 56.91,56.9 - 82.77,82.76 - 95.11,95.1 - 99.99,--,--,--,100.00,No
"Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement",140,Registry/QCDR,Process,Y,20.3 - 41.73,41.72 - 55.66,55.65 - 66.59,66.58 - 75.40,75.39 - 82.52,82.51 - 88.39,88.38 - 93.73,<= 93.72,Yes
"Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement",140,Claims,Process,Y,93.27 - 99.61,99.6 - 99.99,--,--,--,--,--,100.00,Yes
"Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care",141,Registry/QCDR,Outcome,Y,9.16 - 15.58,15.57 - 19.03,19.02 - 22.47,22.46 - 26.68,26.67 - 36.88,36.87 - 67.75,67.74 - 90.71,<= 90.7,Yes
"Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care",141,Claims,Outcome,Y,96.61 - 99.99,--,--,--,--,--,--,100.00,Yes
"Oncology: Medical and Radiation - Pain Intensity Quantified",143,Registry/QCDR,Process,Y,67.46 - 85.89,85.88 - 95.01,95.0 - 97.78,97.77 - 99.54,99.53 - 99.99,--,--,100.00,Yes
"Oncology: Medical and Radiation - Pain Intensity Quantified",143,EHR,Process,Y,46.53 - 77.38,77.37 - 89.11,89.1 - 93.42,93.41 - 95.96,95.95 - 97.44,97.43 - 98.57,98.56 - 99.56,<= 99.55,Yes
"Oncology: Medical and Radiation - Plan of Care for Moderate to Severe Pain",144,Registry/QCDR,Process,Y,30.12 - 64.41,64.4 - 82.53,82.52 - 90.95,90.94 - 96.31,96.3 - 98.77,98.76 - 99.99,--,100.00,Yes
"Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy",145,Claims,Process,Y,58.62 - 86.12,86.11 - 94.45,94.44 - 97.23,97.22 - 98.62,98.61 - 99.99,--,--,100.00,Yes
"Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy",145,Registry/QCDR,Process,Y,47.45 - 79.32,79.31 - 90.78,90.77 - 96.27,96.26 - 98.58,98.57 - 99.71,99.7 - 99.99,--,100.00,Yes
"Radiology: Inappropriate Use of ""Probably Benign" Assessment Category in Screening Mammograms",146,Registry/QCDR,Process,Y,0.66 - 0.26,0.25 - 0.13,0.12 - 0.06,0.05 - 0.02,0.01 - 0.01,--,--,0.00,Yes
"Radiology: Inappropriate Use of ""Probably Benign" Assessment Category in Screening Mammograms",146,Claims,Process,Y,0.51 - 0.20,0.19 - 0.01,--,--,--,--,--,0.00,Yes
"Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy",147,Claims,Process,Y,61.9 - 86.97,86.96 - 95.46,95.45 - 98.16,98.15 - 99.99,--,--,--,100.00,Yes
"Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy",147,Registry/QCDR,Process,Y,76.92 - 91.12,91.11 - 97.39,97.38 - 99.79,99.78 - 99.99,--,--,--,100.00,Yes
"Falls: Risk Assessment",154,Registry/QCDR,Process,Y,30.88 - 67.18,67.17 - 84.65,84.64 - 94.45,94.44 - 98.53,98.52 - 99.99,--,--,100.00,Yes
"Falls: Risk Assessment",154,Claims,Process,Y,89.13 - 98.37,98.36 - 99.99,--,--,--,--,--,100.00,Yes
"Falls: Plan of Care",155,Claims,Process,Y,28.57 - 97.31,97.3 - 99.99,--,--,--,--,--,100.00,Yes
"Falls: Plan of Care",155,Registry/QCDR,Process,Y,26.42 - 57.93,57.92 - 76.37,76.36 - 86.22,86.21 - 94.81,94.8 - 98.07,98.06 - 99.99,--,100.00,Yes
"Oncology: Radiation Dose Limits to Normal Tissues",156,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Diabetes: Foot Exam",163,EHR,Process,Y,2.99 - 9.10,9.09 - 18.13,18.12 - 28.01,28.0 - 40.57,40.56 - 54.28,54.27 - 68.40,68.39 - 82.18,<= 82.17,No
"Coronary Artery Bypass Graft (CABG): Prolonged Intubation",164,Registry/QCDR,Outcome,Y,13.64 - 11.55,11.54 - 8.71,8.7 - 6.83,6.82 - 5.85,5.84 - 4.68,4.67 - 3.98,3.97 - 2.87,<= 2.86,No
"Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate",165,Registry/QCDR,Outcome,Y,1.03 - 0.01,--,--,--,--,--,--,0.00,Yes
"Coronary Artery Bypass Graft (CABG): Stroke",166,Registry/QCDR,Outcome,Y,3.23 - 2.39,2.38 - 1.97,1.96 - 1.46,1.45 - 1.18,1.17 - 0.01,--,--,0.00,Yes
"Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure",167,Registry/QCDR,Outcome,Y,3.85 - 2.97,2.96 - 2.28,2.27 - 1.83,1.82 - 1.34,1.33 - 0.91,0.9 - 0.01,--,0.00,Yes
"Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration",168,Registry/QCDR,Outcome,Y,6.06 - 4.09,4.08 - 3.27,3.26 - 2.32,2.31 - 1.80,1.79 - 1.24,1.23 - 0.88,0.87 - 0.01,0.00,Yes
"Rheumatoid Arthritis (RA): Tuberculosis Screening",176,Registry/QCDR,Process,Y,27.78 - 42.09,42.08 - 59.10,59.09 - 74.47,74.46 - 89.17,89.16 - 95.75,95.74 - 99.99,--,100.00,No
"Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity",177,Registry/QCDR,Process,Y,40.91 - 67.06,67.05 - 78.74,78.73 - 87.97,87.96 - 93.14,93.13 - 96.77,96.76 - 99.62,99.61 - 99.99,100.00,Yes
"Rheumatoid Arthritis (RA): Functional Status Assessment",178,Registry/QCDR,Process,Y,45.46 - 76.60,76.59 - 86.05,86.04 - 91.42,91.41 - 95.59,95.58 - 98.77,98.76 - 99.85,99.84 - 99.99,100.00,Yes
"Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis",179,Registry/QCDR,Process,Y,31.81 - 56.74,56.73 - 73.68,73.67 - 81.87,81.86 - 89.79,89.78 - 96.90,96.89 - 99.99,--,100.00,Yes
"Rheumatoid Arthritis (RA): Glucocorticoid Management",180,Registry/QCDR,Process,Y,40.91 - 61.49,61.48 - 73.24,73.23 - 80.84,80.83 - 87.23,87.22 - 91.80,91.79 - 96.71,96.7 - 99.99,100.00,Yes
"Elder Maltreatment Screen and Follow-Up Plan",181,Registry/QCDR,Process,Y,25.71 - 62.57,62.56 - 71.39,71.38 - 81.40,81.39 - 92.07,92.06 - 98.20,98.19 - 99.83,99.82 - 99.99,100.00,Yes
"Elder Maltreatment Screen and Follow-Up Plan",181,Claims,Process,Y,12.11 - 98.25,98.24 - 99.99,--,--,--,--,--,100.00,Yes
"Functional Outcome Assessment",182,Claims,Process,Y,88.24 - 99.65,99.64 - 99.99,--,--,--,--,--,100.00,Yes
"Functional Outcome Assessment",182,Registry/QCDR,Process,Y,1.39 - 4.80,4.79 - 7.36,7.35 - 16.17,16.16 - 87.14,87.13 - 98.89,98.88 - 99.26,99.25 - 99.92,<= 99.91,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps 
- Avoidance of Inappropriate Use",185,Claims,Process,Y,96.92 - 98.81,98.8 - 99.99,--,--,--,--,--,100.00,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps 
- Avoidance of Inappropriate Use",185,Registry/QCDR,Process,Y,27.27 - 58.34,58.33 - 78.96,78.95 - 94.64,94.63 - 98.06,98.05 - 99.53,99.52 - 99.99,--,100.00,Yes
"Stroke and Stroke Rehabilitation: Thrombolytic Therapy",187,Registry/QCDR,Process,Y,52.94 - 72.23,72.22 - 80.91,80.9 - 92.87,92.86 - 97.31,97.3 - 99.99,--,--,100.00,Yes
"Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery",191,EHR,Outcome,Y,66.87 - 82.84,82.83 - 90.43,90.42 - 94.13,94.12 - 96.16,96.15 - 97.46,97.45 - 98.46,98.45 - 99.28,<= 99.27,No
"Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery",191,Registry/QCDR,Outcome,Y,87.5 - 93.66,93.65 - 96.52,96.51 - 97.79,97.78 - 98.93,98.92 - 99.99,--,--,100.00,No
"Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures",192,EHR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
"Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures",192,Registry/QCDR,Outcome,Y,1.21 - 0.29,0.28 - 0.01,--,--,--,--,--,0.00,Yes
"Radiology: Stenosis Measurement in Carotid Imaging Reports",195,Registry/QCDR,Process,Y,93.52 - 98.15,98.14 - 99.50,99.49 - 99.99,99.98 - 99.99,--,--,--,100.00,Yes
"Radiology: Stenosis Measurement in Carotid Imaging Reports",195,Claims,Process,Y,90.56 - 97.27,97.26 - 99.23,99.22 - 99.99,--,--,--,--,100.00,Yes
"Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet",204,EHR,Process,Y,51.85 - 65.12,65.11 - 70.99,70.98 - 75.62,75.61 - 79.18,79.17 - 82.19,82.18 - 85.01,85.0 - 88.02,<= 88.01,No
"Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet",204,Registry/QCDR,Process,Y,54.31 - 72.50,72.49 - 81.23,81.22 - 85.70,85.69 - 88.62,88.61 - 91.09,91.08 - 93.17,93.16 - 95.37,<= 95.36,No
"Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet",204,Claims,Process,Y,83.19 - 87.37,87.36 - 90.01,90.0 - 92.28,92.27 - 94.24,94.23 - 96.47,96.46 - 99.01,99.0 - 99.99,100.00,No
"Melanoma: Overutilization of Imaging Studies in Melanoma",224,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Radiology: Reminder System for Screening Mammograms",225,Claims,Structure,Y,99.15 - 99.99,--,--,--,--,--,--,100.00,Yes
"Radiology: Reminder System for Screening Mammograms",225,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention",226,Registry/QCDR,Process,Y,10.45 - 19.73,19.72 - 32.09,32.08 - 46.92,46.91 - 65.71,65.7 - 82.99,82.98 - 94.24,94.23 - 99.99,100.00,No
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention",226,Claims,Process,Y,95.86 - 98.57,98.56 - 99.73,99.72 - 99.99,--,--,--,--,100.00,No
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention",226,EHR,Process,Y,7.27 - 17.37,17.36 - 33.34,33.33 - 55.84,55.83 - 73.99,73.98 - 82.97,82.96 - 88.10,88.09 - 92.48,<= 92.47,No
"Controlling High Blood Pressure",236,EHR,IntermediateOutcome,Y,43.06 - 51.69,51.68 - 57.10,57.09 - 61.56,61.55 - 65.44,65.43 - 69.10,69.09 - 72.89,72.88 - 77.30,<= 77.29,No
"Controlling High Blood Pressure",236,Registry/QCDR,IntermediateOutcome,Y,41.75 - 52.31,52.3 - 58.52,58.51 - 64.11,64.1 - 68.71,68.7 - 73.10,73.09 - 78.21,78.2 - 84.38,<= 84.37,No
"Controlling High Blood Pressure",236,Claims,IntermediateOutcome,Y,50.52 - 59.29,59.28 - 65.20,65.19 - 69.79,69.78 - 74.32,74.31 - 78.60,78.59 - 83.62,83.61 - 89.03,<= 89.02,No
"Use of High-Risk Medications in the Elderly",238,EHR,Process,Y,11.49 - 6.11,6.1 - 3.10,3.09 - 1.38,1.37 - 0.58,0.57 - 0.22,0.21 - 0.01,--,0.00,Yes
"Use of High-Risk Medications in the Elderly",238,Registry/QCDR,Process,Y,8.52 - 3.29,3.28 - 1.45,1.44 - 0.67,0.66 - 0.34,0.33 - 0.17,0.16 - 0.01,--,0.00,Yes
"Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents",239,EHR,Process,Y,21.79 - 27.69,27.68 - 30.57,30.56 - 32.13,32.12 - 33.34,33.33 - 34.73,34.72 - 39.98,39.97 - 51.30,<= 51.29,No
"Childhood Immunization Status",240,EHR,Process,Y,5.26 - 11.55,11.54 - 18.91,18.9 - 24.87,24.86 - 29.44,29.43 - 34.27,34.26 - 38.53,38.52 - 43.60,<= 43.59,No
"Cardiac Rehabilitation Patient Referral from an Outpatient Setting",243,Registry/QCDR,Process,Y,2.6 - 5.66,5.65 - 8.90,8.89 - 14.38,14.37 - 20.76,20.75 - 28.85,28.84 - 38.95,38.94 - 52.91,<= 52.9,No
"Barrett's Esophagus",249,Registry/QCDR,Process,Y,99.81 - 99.99,--,--,--,--,--,--,100.00,Yes
"Barrett's Esophagus",249,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Radical Prostatectomy Pathology Reporting",250,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Radical Prostatectomy Pathology Reporting",250,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients",251,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients",251,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain",254,Registry/QCDR,Process,Y,80.37 - 88.72,88.71 - 92.23,92.22 - 94.84,94.83 - 96.31,96.3 - 97.88,97.87 - 99.01,99.0 - 99.99,100.00,No
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,Registry/QCDR,Outcome,Y,85.0 - 85.72,85.71 - 88.25,88.24 - 88.52,88.51 - 91.96,91.95 - 95.25,95.24 - 96.01,96.0 - 97.88,<= 97.87,No
"Image Confirmation of Successful Excision of Image-Localized Breast Lesion",262,Registry/QCDR,Process,Y,99.17 - 99.99,--,--,--,--,--,--,100.00,Yes
"Preoperative Diagnosis of Breast Cancer",263,Registry/QCDR,Process,Y,97.5 - 98.27,98.26 - 99.05,99.04 - 99.99,--,--,--,--,100.00,Yes
"Sentinel Lymph Node Biopsy for Invasive Breast Cancer",264,Registry/QCDR,Process,Y,95.0 - 97.74,97.73 - 98.86,98.85 - 99.45,99.44 - 99.99,--,--,--,100.00,Yes
"Biopsy Follow-Up",265,Registry/QCDR,Process,Y,25.09 - 72.29,72.28 - 89.69,89.68 - 97.52,97.51 - 99.80,99.79 - 99.99,--,--,100.00,Yes
"Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy",268,Registry/QCDR,Process,Y,8.33 - 26.48,26.47 - 33.34,33.33 - 38.31,38.3 - 64.72,64.71 - 81.83,81.82 - 90.01,90.0 - 99.99,100.00,No
"Sleep Apnea: Assessment of Sleep Symptoms",276,Registry/QCDR,Process,Y,4.98 - 17.79,17.78 - 47.20,47.19 - 64.72,64.71 - 79.03,79.02 - 87.55,87.54 - 95.71,95.7 - 99.99,100.00,No
"Sleep Apnea: Severity Assessment at Initial Diagnosis",277,Registry/QCDR,Process,Y,5.68 - 23.95,23.94 - 54.34,54.33 - 80.48,80.47 - 90.64,90.63 - 99.25,99.24 - 99.99,--,100.00,Yes
"Sleep Apnea: Positive Airway Pressure Therapy Prescribed",278,Registry/QCDR,Process,Y,91.0 - 96.49,96.48 - 97.22,97.21 - 98.26,98.25 - 99.35,99.34 - 99.99,--,--,100.00,No
"Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy",279,Registry/QCDR,Process,Y,49.0 - 73.82,73.81 - 88.57,88.56 - 94.02,94.01 - 98.68,98.67 - 99.99,--,--,100.00,Yes
"Dementia: Cognitive Assessment",281,EHR,Process,Y,3.57 - 7.70,7.69 - 14.01,14.0 - 25.79,25.78 - 43.88,43.87 - 67.36,67.35 - 80.73,80.72 - 92.32,<= 92.31,No
"Dementia: Functional Status Assessment",282,Registry/QCDR,Process,Y,28.17 - 57.94,57.93 - 77.90,77.89 - 89.87,89.86 - 96.68,96.67 - 98.69,98.68 - 99.99,--,100.00,Yes
"Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management",283,Registry/QCDR,Process,Y,51.36 - 83.84,83.83 - 94.10,94.09 - 98.06,98.05 - 99.79,99.78 - 99.99,--,--,100.00,Yes
"Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia",286,Registry/QCDR,Process,Y,19.57 - 39.09,39.08 - 78.31,78.3 - 90.92,90.91 - 98.31,98.3 - 99.99,--,--,100.00,Yes
"Dementia: Education and Support of Caregivers for Patients with Dementia",288,Registry/QCDR,Process,Y,13.68 - 38.64,38.63 - 56.01,56.0 - 76.48,76.47 - 86.85,86.84 - 99.99,--,--,100.00,Yes
"Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease",290,Registry/QCDR,Process,Y,8.82 - 16.14,16.13 - 30.01,30.0 - 40.99,40.98 - 51.86,51.85 - 79.32,79.31 - 99.99,--,100.00,Yes
"Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson's Disease",291,Registry/QCDR,Process,Y,10.0 - 33.07,33.06 - 63.48,63.47 - 89.91,89.9 - 99.99,--,--,--,100.00,Yes
"Parkinson's Disease: Rehabilitative Therapy Options",293,Registry/QCDR,Process,Y,23.12 - 37.19,37.18 - 70.01,70.0 - 83.88,83.87 - 95.67,95.66 - 99.99,--,--,100.00,Yes
"Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery",303,Registry/QCDR,PatientReportedOutcome,Y,26.09 - 36.82,36.81 - 48.71,48.7 - 56.68,56.67 - 69.98,69.97 - 82.74,82.73 - 94.24,94.23 - 98.58,<= 98.57,No
"Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery",304,Registry/QCDR,PatientReportedOutcome,Y,16.36 - 27.84,27.83 - 56.18,56.17 - 66.33,66.32 - 75.77,75.76 - 86.40,86.39 - 94.95,94.94 - 98.69,<= 98.68,No
"Initiation and Engagement of Alcohol and Other Drug Dependence Treatment",305,EHR,Process,Y,0.37 - 0.51,0.5 - 0.82,0.81 - 1.16,1.15 - 1.45,1.44 - 1.93,1.92 - 2.76,2.75 - 4.57,<= 4.56,No
"Cervical Cancer Screening",309,EHR,Process,Y,3.41 - 10.65,10.64 - 17.61,17.6 - 24.57,24.56 - 32.11,32.1 - 40.75,40.74 - 49.14,49.13 - 59.18,<= 59.17,No
"Chlamydia Screening for Women",310,EHR,Process,Y,6.9 - 15.23,15.22 - 22.06,22.05 - 28.43,28.42 - 35.14,35.13 - 40.17,40.16 - 46.82,46.81 - 55.82,<= 55.81,No
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented",317,Claims,Process,Y,29.32 - 46.80,46.79 - 67.24,67.23 - 86.82,86.81 - 95.60,95.59 - 98.98,98.97 - 99.99,--,100.00,No
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented",317,EHR,Process,Y,12.25 - 19.62,19.61 - 23.91,23.9 - 27.76,27.75 - 31.42,31.41 - 35.30,35.29 - 40.17,40.16 - 47.42,<= 47.41,No
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented",317,Registry/QCDR,Process,Y,16.37 - 28.68,28.67 - 37.75,37.74 - 45.35,45.34 - 53.76,53.75 - 65.11,65.1 - 84.31,84.3 - 96.70,<= 96.69,No
"Falls: Screening for Future Fall Risk",318,EHR,Process,Y,1.39 - 13.14,13.13 - 30.94,30.93 - 49.09,49.08 - 65.29,65.28 - 77.36,77.35 - 86.63,86.62 - 93.58,<= 93.57,No
"Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients",320,Registry/QCDR,Process,Y,59.09 - 82.77,82.76 - 89.30,89.29 - 92.60,92.59 - 95.12,95.11 - 97.37,97.36 - 98.53,98.52 - 99.99,100.00,Yes
"Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients",320,Claims,Process,Y,85.94 - 93.11,93.1 - 97.17,97.16 - 99.99,--,--,--,--,100.00,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients",322,Registry/QCDR,Efficiency,Y,1.09 - 0.13,0.12 - 0.01,--,--,--,--,--,0.00,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)",323,Registry/QCDR,Efficiency,Y,1.09 - 0.01,--,--,--,--,--,--,0.00,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,Registry/QCDR,Efficiency,Y,21.33 - 8.38,8.37 - 2.18,2.17 - 0.14,0.13 - 0.01,--,--,--,0.00,Yes
"Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy",326,Registry/QCDR,Process,Y,68.06 - 76.46,76.45 - 82.93,82.92 - 87.23,87.22 - 95.05,95.04 - 98.05,98.04 - 99.99,--,100.00,Yes
"Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy",326,Claims,Process,Y,93.14 - 98.47,98.46 - 99.99,--,--,--,--,--,100.00,Yes
"Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)",331,Registry/QCDR,Process,Y,87.18 - 76.10,76.09 - 65.68,65.67 - 54.30,54.29 - 43.60,43.59 - 34.33,34.32 - 23.18,23.17 - 13.05,<= 13.04,No
"Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)",332,Registry/QCDR,Process,Y,58.01 - 79.42,79.41 - 92.32,92.31 - 96.16,96.15 - 98.10,98.09 - 98.98,98.97 - 99.89,99.88 - 99.99,100.00,Yes
"Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)",333,Registry/QCDR,Efficiency,Y,6.37 - 2.71,2.7 - 1.17,1.16 - 0.21,0.2 - 0.01,--,--,--,0.00,Yes
"Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)",334,Registry/QCDR,Efficiency,Y,3.3 - 0.91,0.9 - 0.01,--,--,--,--,--,0.00,Yes
"Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier",337,Registry/QCDR,Process,Y,27.59 - 52.36,52.35 - 71.09,71.08 - 82.19,82.18 - 90.49,90.48 - 95.25,95.24 - 98.59,98.58 - 99.99,100.00,No
"HIV Viral Load Suppression",338,Registry/QCDR,Outcome,Y,49.37 - 59.10,59.09 - 81.83,81.82 - 83.98,83.97 - 86.61,86.6 - 92.70,92.69 - 95.78,95.77 - 99.30,<= 99.29,No
"HIV Medical Visit Frequency",340,Registry/QCDR,Process,Y,40.26 - 48.41,48.4 - 56.04,56.03 - 62.45,62.44 - 70.22,70.21 - 76.93,76.92 - 90.39,90.38 - 95.36,<= 95.35,No
"Pain Brought Under Control Within 48 Hours",342,Registry/QCDR,Outcome,Y,83.99 - 99.52,99.51 - 99.99,--,--,--,--,--,100.00,Yes
"Screening Colonoscopy Adenoma Detection Rate",343,Registry/QCDR,Outcome,Y,17.95 - 28.61,28.6 - 33.65,33.64 - 37.51,37.5 - 41.75,41.74 - 45.31,45.3 - 49.43,49.42 - 60.14,<= 60.13,No
"Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy",350,Registry/QCDR,Process,Y,88.87 - 98.04,98.03 - 99.99,--,--,--,--,--,100.00,Yes
"Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation",351,Registry/QCDR,Process,Y,92.23 - 98.82,98.81 - 99.99,--,--,--,--,--,100.00,Yes
"Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet",352,Registry/QCDR,Process,Y,96.76 - 99.99,--,--,--,--,--,--,100.00,Yes
"Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report",353,Registry/QCDR,Process,Y,97.14 - 99.99,--,--,--,--,--,--,100.00,Yes
"Anastomotic Leak Intervention",354,Registry/QCDR,Outcome,Y,8.7 - 5.01,5.0 - 1.71,1.7 - 0.51,0.5 - 0.01,--,--,--,0.00,Yes
"Unplanned Reoperation within the 30 Day Postoperative Period",355,Registry/QCDR,Outcome,Y,4.69 - 2.59,2.58 - 1.68,1.67 - 0.96,0.95 - 0.37,0.36 - 0.01,--,--,0.00,Yes
"Unplanned Hospital Readmission within 30 Days of Principal Procedure",356,Registry/QCDR,Outcome,Y,6.19 - 3.71,3.7 - 2.63,2.62 - 1.60,1.59 - 0.89,0.88 - 0.01,--,--,0.00,Yes
"Surgical Site Infection (SSI)",357,Registry/QCDR,Outcome,Y,5.58 - 2.26,2.25 - 1.36,1.35 - 0.69,0.68 - 0.01,--,--,--,0.00,Yes
"Patient-Centered Surgical Risk Assessment and Communication",358,Registry/QCDR,Process,Y,4.81 - 35.08,35.07 - 66.86,66.85 - 87.61,87.6 - 97.38,97.37 - 99.99,--,--,100.00,Yes
"Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description",359,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies",360,Registry/QCDR,Process,Y,2.45 - 5.21,5.2 - 37.91,37.9 - 93.78,93.77 - 98.92,98.91 - 99.99,--,--,100.00,Yes
"Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry",361,Registry/QCDR,Structure,Y,98.77 - 99.99,--,--,--,--,--,--,100.00,Yes
"Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes",362,Registry/QCDR,Structure,Y,97.32 - 99.99,--,--,--,--,--,--,100.00,Yes
"Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Studies Through a Secure, Authorized, Media-Free, Shared Archive",363,Registry/QCDR,Structure,Y,93.53 - 99.34,99.33 - 99.99,--,--,--,--,--,100.00,No
"Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines",364,Registry/QCDR,Process,Y,52.4 - 68.10,68.09 - 78.42,78.41 - 85.72,85.71 - 91.81,91.8 - 98.09,98.08 - 99.99,--,100.00,Yes
"Follow-Up Care for Children Prescribed ADHD Medication (ADD)",366,EHR,Process,Y,10.0 - 13.47,13.46 - 16.68,16.67 - 23.28,23.27 - 26.43,26.42 - 29.67,29.66 - 31.68,31.67 - 38.41,<= 38.4,No
"Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use",367,EHR,Process,Y,0.32 - 0.75,0.74 - 2.02,2.01 - 2.83,2.82 - 3.63,3.62 - 4.97,4.96 - 13.11,13.1 - 26.93,<= 26.92,No
"Pregnant women that had HBsAg testing",369,EHR,Process,Y,41.0 - 63.77,63.76 - 75.77,75.76 - 83.79,83.78 - 88.01,88.0 - 90.85,90.84 - 93.93,93.92 - 95.76,<= 95.75,No
"Depression Remission at Twelve Months",370,EHR,Outcome,Y,1.42 - 2.34,2.33 - 3.22,3.21 - 4.63,4.62 - 7.01,7.0 - 9.61,9.6 - 14.30,14.29 - 20.27,<= 20.26,No
"Depression Utilization of the PHQ-9 Tool",371,EHR,Process,Y,2.48 - 4.47,4.46 - 7.27,7.26 - 10.45,10.44 - 14.44,14.43 - 19.59,19.58 - 25.72,25.71 - 35.42,<= 35.41,No
"Maternal Depression Screening",372,EHR,Process,Y,3.54 - 5.01,5.0 - 17.01,17.0 - 23.01,23.0 - 30.71,30.7 - 35.72,35.71 - 42.60,42.59 - 58.39,<= 58.38,No
"Hypertension: Improvement in Blood Pressure",373,EHR,IntermediateOutcome,Y,12.16 - 18.53,18.52 - 24.04,24.03 - 29.04,29.03 - 33.18,33.17 - 37.00,36.99 - 40.75,40.74 - 44.75,<= 44.74,No
"Closing the Referral Loop: Receipt of Specialist Report",374,Registry/QCDR,Process,Y,5.66 - 36.61,36.6 - 68.65,68.64 - 87.21,87.2 - 96.22,96.21 - 99.99,--,--,100.00,No
"Closing the Referral Loop: Receipt of Specialist Report",374,EHR,Process,Y,2.63 - 7.01,7.0 - 14.82,14.81 - 25.96,25.95 - 37.71,37.7 - 50.01,50.0 - 62.17,62.16 - 75.24,<= 75.23,No
"Functional Status Assessment for Total Knee Replacement",375,EHR,Process,Y,1.43 - 2.34,2.33 - 4.36,4.35 - 7.20,7.19 - 15.01,15.0 - 26.68,26.67 - 37.05,37.04 - 55.57,<= 55.56,No
"Functional Status Assessment for Total Hip Replacement",376,EHR,Process,Y,1.56 - 3.30,3.29 - 5.01,5.0 - 10.76,10.75 - 17.79,17.78 - 23.30,23.29 - 35.21,35.2 - 48.15,<= 48.14,No
"Functional Status Assessments for Congestive Heart Failure",377,EHR,Process,Y,0.63 - 1.23,1.22 - 2.01,2.0 - 3.01,3.0 - 4.13,4.12 - 5.29,5.28 - 5.88,5.87 - 9.81,<= 9.8,No
"Children Who Have Dental Decay or Cavities",378,EHR,Outcome,Y,1.37 - 0.59,0.58 - 0.14,0.13 - 0.01,--,--,--,--,0.00,Yes
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,EHR,Process,Y,0.06 - 0.22,0.21 - 0.52,0.51 - 1.09,1.08 - 2.42,2.41 - 3.57,3.56 - 4.77,4.76 - 7.05,<= 7.04,No
"Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment",382,EHR,Process,Y,1.49 - 5.37,5.36 - 12.85,12.84 - 20.38,20.37 - 27.98,27.97 - 36.01,36.0 - 46.16,46.15 - 65.89,<= 65.88,No
"Adherence to Antipsychotic Medications For Individuals with Schizophrenia",383,Registry/QCDR,IntermediateOutcome,Y,39.13 - 73.22,73.21 - 81.76,81.75 - 90.01,90.0 - 98.86,98.85 - 99.99,--,--,100.00,No
"Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery",384,Registry/QCDR,Outcome,Y,91.43 - 97.72,97.71 - 99.99,--,--,--,--,--,100.00,No
"Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery",385,Registry/QCDR,Outcome,Y,9.09 - 13.10,13.09 - 16.34,16.33 - 19.24,19.23 - 21.77,21.76 - 24.74,24.73 - 30.26,30.25 - 34.79,<= 34.78,No
"Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy)",388,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
"Cataract Surgery: Difference Between Planned and Final Refraction",389,Registry/QCDR,Outcome,Y,0.45 - 0.71,0.7 - 0.96,0.95 - 1.18,1.17 - 1.50,1.49 - 1.91,1.9 - 2.57,2.56 - 17.10,<= 17.09,No
"Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options",390,Registry/QCDR,Process,Y,36.62 - 53.60,53.59 - 76.25,76.24 - 89.18,89.17 - 99.99,--,--,--,100.00,Yes
"Immunizations for Adolescents",394,Registry/QCDR,Process,Y,1.75 - 2.45,2.44 - 4.77,4.76 - 6.68,6.67 - 13.80,13.79 - 15.01,15.0 - 16.68,16.67 - 27.60,<= 27.59,No
"Lung Cancer Reporting (Biopsy/Cytology Specimens)",395,Registry/QCDR,Process,Y,99.62 - 99.99,--,--,--,--,--,--,100.00,Yes
"Lung Cancer Reporting (Biopsy/Cytology Specimens)",395,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Lung Cancer Reporting (Resection Specimens)",396,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Melanoma Reporting",397,Registry/QCDR,Process,Y,90.68 - 99.99,--,--,--,--,--,--,100.00,Yes
"Melanoma Reporting",397,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Optimal Asthma Control",398,Registry/QCDR,Outcome,Y,15.5 - 41.13,41.12 - 54.18,54.17 - 73.50,73.49 - 84.59,84.58 - 96.73,96.72 - 99.99,--,100.00,No
"One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk",400,Registry/QCDR,Process,Y,0.39 - 0.96,0.95 - 1.68,1.67 - 2.42,2.41 - 3.92,3.91 - 10.59,10.58 - 39.37,39.36 - 54.96,<= 54.95,No
"Tobacco Use and Help with Quitting Among Adolescents",402,Registry/QCDR,Process,Y,77.35 - 87.64,87.63 - 92.51,92.5 - 95.25,95.24 - 97.07,97.06 - 98.42,98.41 - 99.41,99.4 - 99.99,100.00,Yes
"Anesthesiology Smoking Abstinence",404,Registry/QCDR,IntermediateOutcome,Y,36.24 - 46.54,46.53 - 56.40,56.39 - 62.93,62.92 - 69.57,69.56 - 75.01,75.0 - 79.34,79.33 - 90.11,<= 90.1,No
"Appropriate Follow-up Imaging for Incidental Abdominal Lesions",405,Registry/QCDR,Process,Y,10.66 - 2.71,2.7 - 0.16,0.15 - 0.01,--,--,--,--,0.00,Yes
"Appropriate Follow-up Imaging for Incidental Abdominal Lesions",405,Claims,Process,Y,19.59 - 4.56,4.55 - 0.01,--,--,--,--,--,0.00,Yes
"Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients",406,Registry/QCDR,Process,Y,17.39 - 7.33,7.32 - 3.40,3.39 - 0.75,0.74 - 0.01,--,--,--,0.00,No
"Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients",406,Claims,Process,Y,5.32 - 2.02,2.01 - 0.01,--,--,--,--,--,0.00,No
"Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia",407,Registry/QCDR,Process,Y,80.95 - 96.07,96.06 - 98.42,98.41 - 99.99,--,--,--,--,100.00,Yes
"Opioid Therapy Follow-up Evaluation",408,Registry/QCDR,Process,Y,28.4 - 68.36,68.35 - 81.52,81.51 - 94.25,94.24 - 98.92,98.91 - 99.99,--,--,100.00,Yes
"Psoriasis: Clinical Response to Systemic Medications",410,Registry/QCDR,Outcome,Y,14.85 - 34.79,34.78 - 51.29,51.28 - 64.30,64.29 - 76.74,76.73 - 85.38,85.37 - 93.76,93.75 - 99.99,100.00,No
"Documentation of Signed Opioid Treatment Agreement",412,Registry/QCDR,Process,Y,40.91 - 70.99,70.98 - 84.01,84.0 - 96.93,96.92 - 99.99,--,--,--,100.00,Yes
"Evaluation or Interview for Risk of Opioid Misuse",414,Registry/QCDR,Process,Y,58.16 - 91.75,91.74 - 98.32,98.31 - 99.54,99.53 - 99.99,--,--,--,100.00,Yes
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older",415,Registry/QCDR,Efficiency,Y,58.18 - 67.87,67.86 - 76.48,76.47 - 85.20,85.19 - 93.57,93.56 - 97.53,97.52 - 98.82,98.81 - 99.99,100.00,Yes
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older",415,Claims,Efficiency,Y,85.19 - 93.34,93.33 - 96.16,96.15 - 99.99,--,--,--,--,100.00,Yes
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years",416,Registry/QCDR,Efficiency,Y,40.82 - 33.56,33.55 - 27.74,27.73 - 22.60,22.59 - 15.64,15.63 - 9.39,9.38 - 3.93,3.92 - 1.46,<= 1.45,No
"Osteoporosis Management in Women Who Had a Fracture",418,Registry/QCDR,Process,Y,2.04 - 2.95,2.94 - 3.71,3.7 - 4.85,4.84 - 9.53,9.52 - 18.47,18.46 - 31.33,31.32 - 45.84,<= 45.83,No
"Overuse of Imaging for the Evaluation of Primary Headache",419,Registry/QCDR,Process,Y,76.19 - 81.91,81.9 - 86.90,86.89 - 89.81,89.8 - 92.60,92.59 - 94.72,94.71 - 96.44,96.43 - 99.99,100.00,No
"Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy",423,Registry/QCDR,Process,Y,93.94 - 96.16,96.15 - 99.80,99.79 - 99.99,--,--,--,--,100.00,No
"Perioperative Temperature Management",424,Registry/QCDR,Outcome,Y,91.69 - 97.68,97.67 - 99.44,99.43 - 99.75,99.74 - 99.87,99.86 - 99.96,99.95 - 99.99,--,100.00,Yes
"Photodocumentation of Cecal Intubation",425,Registry/QCDR,Process,Y,95.78 - 97.73,97.72 - 98.42,98.41 - 98.81,98.8 - 99.19,99.18 - 99.40,99.39 - 99.63,99.62 - 99.92,<= 99.91,Yes
"Photodocumentation of Cecal Intubation",425,Claims,Process,Y,93.55 - 98.19,98.18 - 99.06,99.05 - 99.51,99.5 - 99.99,--,--,--,100.00,Yes
"Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit (PACU)",426,Registry/QCDR,Process,Y,94.09 - 99.17,99.16 - 99.79,99.78 - 99.93,99.92 - 100.00,99.99 - 99.99,--,--,100.00,Yes
"Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU)",427,Registry/QCDR,Process,Y,83.78 - 94.91,94.9 - 97.38,97.37 - 98.77,98.76 - 99.51,99.5 - 99.99,--,--,100.00,Yes
"Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy",430,Registry/QCDR,Process,Y,87.8 - 94.71,94.7 - 97.31,97.3 - 98.59,98.58 - 99.28,99.27 - 99.68,99.67 - 99.90,99.89 - 99.99,100.00,Yes
"Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling",431,Registry/QCDR,Process,Y,11.22 - 35.61,35.6 - 52.50,52.49 - 69.35,69.34 - 81.59,81.58 - 89.89,89.88 - 95.11,95.1 - 98.76,<= 98.75,No
"Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair",432,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,No
"Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair",433,Registry/QCDR,Outcome,Y,0.45 - 0.01,--,--,--,--,--,--,0.00,No
"Quality of Life Assessment For Patients With Primary Headache Disorders",435,Registry/QCDR,PatientReportedOutcome,Y,3.13 - 4.77,4.76 - 14.30,14.29 - 36.85,36.84 - 49.10,49.09 - 80.57,80.56 - 99.99,--,100.00,No
"Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques",436,Registry/QCDR,Process,Y,85.14 - 96.88,96.87 - 99.09,99.08 - 99.71,99.7 - 99.94,99.93 - 99.99,--,--,100.00,Yes
"Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques",436,Claims,Process,Y,90.17 - 97.42,97.41 - 99.09,99.08 - 99.69,99.68 - 99.91,99.9 - 99.99,--,--,100.00,Yes
"Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure",437,Claims,Outcome,Y,2.94 - 2.09,2.08 - 1.86,1.85 - 1.09,1.08 - 0.01,--,--,--,0.00,Yes
"Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure",437,Registry/QCDR,Outcome,Y,7.36 - 2.87,2.86 - 0.01,--,--,--,--,--,0.00,Yes
"Statin Therapy for the Prevention and Treatment of Cardiovascular Disease",438,EHR,Process,Y,42.18 - 57.15,57.14 - 63.21,63.2 - 66.86,66.85 - 69.84,69.83 - 72.97,72.96 - 75.60,75.59 - 78.58,<= 78.57,Yes
"Statin Therapy for the Prevention and Treatment of Cardiovascular Disease",438,Registry/QCDR,Process,Y,64.16 - 72.89,72.88 - 78.89,78.88 - 85.64,85.63 - 91.68,91.67 - 95.25,95.24 - 99.61,99.6 - 99.99,100.00,Yes
"Age Appropriate Screening Colonoscopy",439,Registry/QCDR,Efficiency,Y,36.84 - 0.64,0.63 - 0.01,--,--,--,--,--,0.00,No
"Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time - Pathologist to Clinician",440,Registry/QCDR,Process,Y,91.93 - 98.73,98.72 - 99.63,99.62 - 99.99,--,--,--,--,100.00,Yes
"Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)",441,Registry/QCDR,IntermediateOutcome,Y,20.64 - 36.96,36.95 - 45.54,45.53 - 52.79,52.78 - 58.99,58.98 - 63.65,63.64 - 66.91,66.9 - 71.84,<= 71.83,No
"Non-Recommended Cervical Cancer Screening in Adolescent Females",443,Registry/QCDR,Process,Y,3.68 - 2.75,2.74 - 1.93,1.92 - 1.73,1.72 - 0.01,--,--,--,0.00,No
"Medication Management for People with Asthma",444,Registry/QCDR,Process,Y,55.33 - 73.72,73.71 - 80.35,80.34 - 91.31,91.3 - 96.68,96.67 - 99.99,--,--,100.00,Yes
"Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)",445,Registry/QCDR,Outcome,Y,5.56 - 3.18,3.17 - 2.82,2.81 - 2.34,2.33 - 1.88,1.87 - 1.40,1.39 - 1.03,1.02 - 0.01,0.00,No
"HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies",449,Registry/QCDR,Process,Y,89.29 - 93.49,93.48 - 97.70,97.69 - 98.88,98.87 - 99.99,--,--,--,100.00,Yes
"Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better)",453,Registry/QCDR,Process,Y,20.0 - 17.29,17.28 - 14.30,14.29 - 12.01,12.0 - 10.01,10.0 - 8.83,8.82 - 7.01,7.0 - 5.46,<= 5.45,No
"Percentage of Patients Who Died From Cancer Not Admitted To Hospice (lower score - better)",456,Registry/QCDR,Process,Y,93.22 - 84.01,84.0 - 77.28,77.27 - 75.61,75.6 - 68.34,68.33 - 64.53,64.52 - 60.69,60.68 - 54.56,<= 54.55,No
"Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better)",457,Registry/QCDR,Outcome,Y,18.9 - 15.83,15.82 - 14.49,14.48 - 12.32,12.31 - 10.01,10.0 - 8.56,8.55 - 6.71,6.7 - 4.78,<= 4.77,No
"Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics)",463,Registry/QCDR,Process,Y,91.18 - 94.83,94.82 - 96.33,96.32 - 97.87,97.86 - 98.58,98.57 - 99.19,99.18 - 99.75,99.74 - 99.99,100.00,No
"Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use",464,Registry/QCDR,Process,Y,80.0 - 86.74,86.73 - 89.02,89.01 - 92.02,92.01 - 94.82,94.81 - 96.06,96.05 - 97.72,97.71 - 99.99,100.00,No
"Psoriasis: Assessment of Psoriasis Disease Activity",AAD1,Registry/QCDR,Process,Y,6.74 - 13.47,13.46 - 28.31,28.3 - 45.19,45.18 - 60.34,60.33 - 72.78,72.77 - 84.06,84.05 - 90.13,<= 90.12,No
"Psoriasis: Screening for Psoriatic Arthritis",AAD2,Registry/QCDR,Process,Y,6.64 - 15.95,15.94 - 36.19,36.18 - 59.75,59.74 - 78.21,78.2 - 85.37,85.36 - 91.87,91.86 - 98.79,<= 98.78,Yes
"Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients",AAD3,Registry/QCDR,Process,Y,6.15 - 4.01,4.0 - 1.81,1.8 - 0.01,--,--,--,--,0.00,Yes
"Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk",AAD4,Registry/QCDR,Process,Y,11.11 - 3.17,3.16 - 1.40,1.39 - 0.01,--,--,--,--,0.00,No
"Biopsy: Reporting Time - Clinician to Patient",AAD5,Registry/QCDR,Process,Y,82.93 - 95.66,95.65 - 98.32,98.31 - 99.99,--,--,--,--,100.00,Yes
"Diabetes/Pre-Diabetes Screening for Patients with DSP",AAN1,Registry/QCDR,Process,Y,4.35 - 9.44,9.43 - 11.12,11.11 - 17.87,17.86 - 20.52,20.51 - 22.42,22.41 - 35.30,35.29 - 63.17,<= 63.16,No
"Falls screening (aggregation of AAN disease specific falls measures)",AAN10,Registry/QCDR,Process,Y,2.01 - 3.82,3.81 - 6.59,6.58 - 9.45,9.44 - 15.27,15.26 - 19.83,19.82 - 34.00,33.99 - 41.20,<= 41.19,No
"Screening for Psychiatric or Behavioral Health Disorders",AAN4,Registry/QCDR,Process,Y,23.48 - 31.26,31.25 - 43.49,43.48 - 62.31,62.3 - 81.91,81.9 - 89.15,89.14 - 94.82,94.81 - 98.43,<= 98.42,No
"Medication Prescribed For Acute Migraine Attack",AAN5,Registry/QCDR,Process,Y,39.73 - 47.50,47.49 - 56.94,56.93 - 61.26,61.25 - 65.64,65.63 - 69.87,69.86 - 73.38,73.37 - 77.79,<= 77.78,No
"Exercise and Appropriate Physical Activity Counseling for Patients with MS",AAN8,Registry/QCDR,Process,Y,38.41 - 47.49,47.48 - 62.64,62.63 - 73.42,73.41 - 78.46,78.45 - 87.51,87.5 - 91.90,91.89 - 95.95,<= 95.94,No
"Querying About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease",AAN9,Registry/QCDR,Process,Y,3.13 - 13.22,13.21 - 35.49,35.48 - 53.67,53.66 - 78.68,78.67 - 88.01,88.0 - 92.60,92.59 - 95.57,<= 95.56,No
"Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids",AAO11,Registry/QCDR,Process,Y,99.23 - 99.71,99.7 - 99.99,--,--,--,--,--,100.00,Yes
"Percentage of patients with cerumen impaction and a suggestive history of a non-intact tympanic membrane who receive just manual removal.",AAO15,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,No
"Age-related Hearing Loss: Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric SNHL",AAO17,Registry/QCDR,Process,Y,97.59 - 98.52,98.51 - 98.85,98.84 - 99.39,99.38 - 99.99,--,--,--,100.00,No
"Percentage of patients with allergic rhinitis who do not receive sinonasal imaging for allergic rhinitis",AAO22,Registry/QCDR,Process,Y,92.7 - 95.13,95.12 - 96.74,96.73 - 97.71,97.7 - 98.56,98.55 - 99.71,99.7 - 99.99,--,100.00,No
"Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines",AAO23,Registry/QCDR,Process,Y,47.1 - 62.80,62.79 - 67.57,67.56 - 70.51,70.5 - 74.56,74.55 - 75.66,75.65 - 78.54,78.53 - 83.21,<= 83.2,No
"Allergic Rhinitis: Avoidance of Leukotriene Inhibitors",AAO24,Registry/QCDR,Process,Y,87.66 - 91.54,91.53 - 93.15,93.14 - 95.49,95.48 - 96.58,96.57 - 97.18,97.17 - 98.15,98.14 - 98.76,<= 98.75,No
"Percentage of patients with allergic rhinitis who do not receive IgG-based immunoglobulin testing",AAO25,Registry/QCDR,Process,Y,99.94 - 99.99,--,--,--,--,--,--,100.00,No
"Otitis Media with Effusion: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility",AAO26,Registry/QCDR,Process,Y,4.76 - 40.51,40.5 - 49.58,49.57 - 53.34,53.33 - 65.65,65.64 - 74.30,74.29 - 79.14,79.13 - 81.45,<= 81.44,No
"Tympanostomy Tubes: Resolution of Otitis Media with Effusion in Adults",AAO28,Registry/QCDR,Outcome,Y,5.0 - 10.01,10.0 - 12.13,12.12 - 15.92,15.91 - 18.95,18.94 - 21.82,21.81 - 26.93,26.92 - 38.72,<= 38.71,No
"Otitis Media with Effusion: Antihistamines or Decongestants  Avoidance of Inappropriate Use",AAO8,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
"Intra-operative anesthesia safety",ABG1,Registry/QCDR,Outcome,Y,99.81 - 99.91,99.9 - 99.97,99.96 - 99.99,--,--,--,--,100.00,Yes
"Planned use of difficult airway equipment",ABG16,Registry/QCDR,Process,Y,29.49 - 44.00,43.99 - 63.34,63.33 - 73.18,73.17 - 80.24,80.23 - 84.43,84.42 - 90.71,90.7 - 93.31,<= 93.3,No
"Pre-operative OSA assessment",ABG21,Registry/QCDR,Process,Y,69.61 - 85.56,85.55 - 92.80,92.79 - 96.74,96.73 - 99.09,99.08 - 99.93,99.92 - 99.99,--,100.00,No
"Pre-Operative Screening for GERD",ABG28,Registry/QCDR,Process,Y,68.08 - 82.01,82.0 - 93.23,93.22 - 97.61,97.6 - 99.78,99.77 - 99.99,--,--,100.00,No
"Pre-Operative Screening for Glaucoma",ABG29,Registry/QCDR,Process,Y,33.65 - 57.52,57.51 - 73.58,73.57 - 85.37,85.36 - 93.77,93.76 - 99.76,99.75 - 99.99,--,100.00,Yes
"Pre-Operative Screening for PONV Risk",ABG30,Registry/QCDR,Process,Y,10.49 - 40.81,40.8 - 73.13,73.12 - 99.76,99.75 - 99.96,99.95 - 99.99,--,--,100.00,Yes
"Pre-Operative Screening for Excessive Alcohol and Recreational Drug Use",ABG31,Registry/QCDR,Process,Y,56.98 - 72.59,72.58 - 84.63,84.62 - 93.03,93.02 - 99.93,99.92 - 99.99,--,--,100.00,Yes
"Corneal Abrasion",ABG36,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,No
"Immediate Adult Post-Operative Pain Management",ABG7,Registry/QCDR,Outcome,Y,97.63 - 98.91,98.9 - 99.51,99.5 - 99.77,99.76 - 99.88,99.87 - 99.96,99.95 - 99.99,--,100.00,Yes
"ACCPin3 Heart Failure: Patient Self Care Education",ACCPIN3,Registry/QCDR,Process,Y,8.51 - 41.93,41.92 - 62.23,62.22 - 76.24,76.23 - 85.72,85.71 - 88.82,88.81 - 92.60,92.59 - 95.26,<= 95.25,Yes
"Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older",ACEP19,Registry/QCDR,Process,Y,50.45 - 53.88,53.87 - 54.79,54.78 - 57.78,57.77 - 59.80,59.79 - 62.90,62.89 - 68.14,68.13 - 74.09,<= 74.08,No
"Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding",ACEP21,Registry/QCDR,Process,Y,19.29 - 14.68,14.67 - 13.41,13.4 - 9.59,9.58 - 8.39,8.38 - 6.07,6.06 - 5.10,5.09 - 3.92,<= 3.91,No
"Pregnancy Test for Female Abdominal Pain Patients",ACEP24,Registry/QCDR,Process,Y,69.7 - 74.64,74.63 - 77.23,77.22 - 79.79,79.78 - 81.96,81.95 - 83.18,83.17 - 86.01,86.0 - 88.58,<= 88.57,No
"Tobacco Use:  Screening and Cessation Intervention for Patients with Asthma and COPD",ACEP25,Registry/QCDR,Process,Y,35.52 - 43.98,43.97 - 50.96,50.95 - 59.39,59.38 - 62.27,62.26 - 65.77,65.76 - 69.42,69.41 - 76.82,<= 76.81,No
"Sepsis Management: Septic Shock: Repeat Lactate Level Measurement",ACEP29,Registry/QCDR,Process,Y,63.27 - 72.87,72.86 - 78.27,78.26 - 84.92,84.91 - 87.24,87.23 - 89.30,89.29 - 90.64,90.63 - 92.69,<= 92.68,No
"Sepsis Management: Septic Shock: Lactate Clearance Rate of >= 10%",ACEP30,Registry/QCDR,Outcome,Y,68.56 - 70.33,70.32 - 72.56,72.55 - 73.69,73.68 - 76.45,76.44 - 77.58,77.57 - 80.96,80.95 - 82.23,<= 82.22,No
"Appropriate Foley catheter use in the emergency department",ACEP31,Registry/QCDR,Process,Y,63.27 - 81.83,81.82 - 84.07,84.06 - 87.26,87.25 - 91.03,91.02 - 97.68,97.67 - 99.69,99.68 - 99.99,100.00,No
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients",ACEP32,Registry/QCDR,Outcome,Y,281.0 - 212.01,212.0 - 189.01,189.0 - 177.01,177.0 - 169.01,169.0 - 158.01,158.0 - 148.01,148.0 - 140.01,<= 140.0,No
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients",ACEP40,Registry/QCDR,Outcome,Y,196.0 - 151.01,151.0 - 135.51,135.5 - 128.01,128.0 - 118.01,118.0 - 114.01,114.0 - 108.51,108.5 - 99.01,<= 99.0,No
"Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,Registry/QCDR,Process,Y,60.0 - 68.38,68.37 - 74.37,74.36 - 77.28,77.27 - 81.81,81.8 - 84.86,84.85 - 86.61,86.6 - 88.72,<= 88.71,No
"COPD Exacerbation: % of patients discharged from inpatient status on Long Acting Beta Agonist (LABA) bronchodilator",ACQR2,Registry/QCDR,Process,Y,91.3 - 94.36,94.35 - 94.93,94.92 - 95.18,95.17 - 95.86,95.85 - 96.16,96.15 - 96.84,96.83 - 97.62,<= 97.61,No
"COPD: Steroids for no more than 5 days in COPD Exacerbation",ACQR3,Registry/QCDR,Efficiency,Y,86.25 - 88.15,88.14 - 89.09,89.08 - 90.98,90.97 - 92.68,92.67 - 93.67,93.66 - 93.76,93.75 - 95.41,<= 95.4,No
"CHF: Document AHA/ACC staging of CHF (A-D)",ACQR5,Registry/QCDR,Process,Y,67.28 - 77.13,77.12 - 80.66,80.65 - 81.64,81.63 - 83.72,83.71 - 85.81,85.8 - 87.16,87.15 - 90.43,<= 90.42,No
"Stroke/TIA: % of patients discharged on antithrombotic therapy",ACQR8,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,No
"Gout: Serum Urate Target",ACR7,Registry/QCDR,IntermediateOutcome,Y,24.19 - 35.72,35.71 - 45.32,45.31 - 50.01,50.0 - 55.45,55.44 - 60.01,60.0 - 63.34,63.33 - 69.35,<= 69.34,No
"Report Turnaround Time: Radiography",ACRAD15,Registry/QCDR,Outcome,Y,53.0 - 8.01,8.0 - 4.01,4.0 - 2.01,2.0 - 2.01,2.0 - 1.01,1.0 - 1.01,1.0 - 0.01,0.00,No
"Report Turnaround Time: Ultrasound (Excluding Breast US)",ACRAD16,Registry/QCDR,Outcome,Y,82.0 - 6.01,6.0 - 4.01,4.0 - 3.01,3.0 - 2.01,2.0 - 1.01,1.0 - 1.01,1.0 - 1.01,<= 1.0,No
"Report Turnaround Time: MRI",ACRAD17,Registry/QCDR,Outcome,Y,111.0 - 15.01,15.0 - 9.01,9.0 - 7.01,7.0 - 6.01,6.0 - 5.01,5.0 - 4.01,4.0 - 3.01,<= 3.0,No
"Report Turnaround Time: CT",ACRAD18,Registry/QCDR,Outcome,Y,37.0 - 6.01,6.0 - 3.01,3.0 - 2.01,2.0 - 1.01,1.0 - 1.01,1.0 - 1.01,1.0 - 0.01,0.00,No
"Report Turnaround Time: PET",ACRAD19,Registry/QCDR,Outcome,Y,111.0 - 43.01,43.0 - 25.01,25.0 - 19.01,19.0 - 16.01,16.0 - 8.51,8.5 - 6.01,6.0 - 4.01,<= 4.0,No
"Lung Cancer Screening Abnormal Interpretation Rate",ACRAD23,Registry/QCDR,Outcome,Y,25.24 - 21.45,21.44 - 18.16,18.15 - 17.14,17.13 - 15.70,15.69 - 14.15,14.14 - 12.51,12.5 - 11.43,<= 11.42,No
"Report Turnaround Time: Mammography",ACRAD25,Registry/QCDR,Outcome,Y,1573.0 - 50.01,50.0 - 33.01,33.0 - 20.01,20.0 - 15.01,15.0 - 11.01,11.0 - 8.01,8.0 - 5.01,<= 5.0,No
"Screening Mammography Cancer Detection Rate (CDR)",ACRAD3,Registry/QCDR,Outcome,Y,0.22 - 0.32,0.31 - 0.36,0.35 - 0.42,0.41 - 0.45,0.44 - 0.50,0.49 - 0.56,0.55 - 0.58,<= 0.57,No
"Percent of CT Abdomen-pelvis exams with contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.",ACRAD31,Registry/QCDR,Outcome,Y,59.36 - 72.37,72.36 - 80.98,80.97 - 86.45,86.44 - 87.16,87.15 - 87.16,87.15 - 92.58,92.57 - 96.30,<= 96.29,Yes
"Percent of CT Chest exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.",ACRAD32,Registry/QCDR,Outcome,Y,70.52 - 73.90,73.89 - 75.84,75.83 - 76.36,76.35 - 84.82,84.81 - 88.03,88.02 - 95.39,95.38 - 98.76,<= 98.75,Yes
"Percent of CT Head/Brain exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level",ACRAD33,Registry/QCDR,Outcome,Y,30.73 - 30.74,30.73 - 61.22,61.21 - 75.73,75.72 - 80.41,80.4 - 91.14,91.13 - 93.64,93.63 - 97.54,<= 97.53,Yes
"Screening Mammography Abnormal Interpretation Rate (Recall Rate)",ACRAD5,Registry/QCDR,Outcome,Y,14.91 - 12.96,12.95 - 10.31,10.3 - 8.97,8.96 - 8.62,8.61 - 7.67,7.66 - 5.98,5.97 - 4.24,<= 4.23,No
"Screening Mammography Positive Predictive Value 2 (PPV2 - Biopsy Recommended)",ACRAD6,Registry/QCDR,Outcome,Y,17.32 - 21.85,21.84 - 23.90,23.89 - 24.75,24.74 - 27.32,27.31 - 29.00,28.99 - 30.57,30.56 - 32.09,<= 32.08,No
"Patient-Reported Experience with Anesthesia",AQI48,Registry/QCDR,Outcome,Y,91.07 - 92.34,92.33 - 93.23,93.22 - 94.22,94.21 - 94.96,94.95 - 95.57,95.56 - 95.96,95.95 - 96.70,<= 96.69,Yes
"Application of Lung-Protective Ventilation during General Anesthesia",AQI50,Registry/QCDR,IntermediateOutcome,Y,98.96 - 99.51,99.5 - 99.73,99.72 - 99.87,99.86 - 99.99,--,--,--,100.00,Yes
"Assessment of Patients for Obstructive Sleep Apnea",AQI51,Registry/QCDR,Process,Y,39.23 - 79.16,79.15 - 90.57,90.56 - 95.91,95.9 - 99.13,99.12 - 99.80,99.79 - 99.99,99.98 - 99.99,100.00,Yes
"Documentation of Anticoagulant and Antiplatelet Medications when Performing Neuraxial Anesthesia/Analgesia or Interventional Pain Procedures",AQI53,Registry/QCDR,Process,Y,56.25 - 74.02,74.01 - 76.88,76.87 - 94.47,94.46 - 98.09,98.08 - 99.99,--,--,100.00,No
"Use of Pencil-Point Needle for Spinal Anesthesia",AQI54,Registry/QCDR,Process,Y,90.22 - 97.45,97.44 - 98.54,98.53 - 99.38,99.37 - 99.82,99.81 - 99.99,--,--,100.00,No
"Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA)",AQI56,Registry/QCDR,Process,Y,72.61 - 91.73,91.72 - 94.76,94.75 - 96.50,96.49 - 98.17,98.16 - 98.60,98.59 - 99.86,99.85 - 99.99,100.00,No
"Multimodal Pain Management",AQI59,Registry/QCDR,Process,Y,69.14 - 80.48,80.47 - 85.13,85.12 - 89.46,89.45 - 92.77,92.76 - 95.89,95.88 - 97.73,97.72 - 99.70,<= 99.69,No
"New Corneal Injury Not Diagnosed Prior to Discharge",AQI60,Registry/QCDR,Outcome,Y,99.87 - 99.95,99.94 - 99.99,99.98 - 100.00,99.99 - 99.99,--,--,--,100.00,No
"Stones: Urinalysis documented 30 days before surgical stone procedures",AQUA15,Registry/QCDR,Process,Y,34.55 - 52.47,52.46 - 65.58,65.57 - 72.74,72.73 - 76.87,76.86 - 82.24,82.23 - 85.98,85.97 - 88.63,<= 88.62,No
"Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis",AQUA18,Registry/QCDR,Process,Y,78.05 - 80.78,80.77 - 88.15,88.14 - 91.49,91.48 - 93.95,93.94 - 96.31,96.3 - 99.99,--,100.00,No
"Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia",AQUA26,Registry/QCDR,Process,Y,16.45 - 10.07,10.06 - 8.74,8.73 - 7.37,7.36 - 6.83,6.82 - 5.17,5.16 - 3.48,3.47 - 3.02,<= 3.01,No
"Hospital admissions/complications within 30 days of TRUS Biopsy",AQUA8,Registry/QCDR,Outcome,Y,6.77 - 4.75,4.74 - 2.62,2.61 - 1.69,1.68 - 0.01,--,--,--,0.00,Yes
"Surgeon assessment for hereditary cause of breast cancer",ASBS1,Registry/QCDR,Process,Y,95.93 - 98.76,98.75 - 99.99,--,--,--,--,--,100.00,Yes
"Return to the operating room for re-excision of previous microscopically negative margins in invasive breast cancer patients undergoing breast conserving therapy",ASBS12,Registry/QCDR,Outcome,Y,96.12 - 98.16,98.15 - 99.99,--,--,--,--,--,100.00,No
"Unplanned 30 day re-operation after mastectomy",ASBS7,Registry/QCDR,Outcome,Y,95.0 - 95.66,95.65 - 98.37,98.36 - 98.76,98.75 - 99.99,--,--,--,100.00,Yes
"Avoid Head CT for Patients with Uncomplicated Syncope",ECPR39,Registry/QCDR,Process,Y,95.83 - 97.45,97.44 - 99.08,99.07 - 99.78,99.77 - 99.99,--,--,--,100.00,No
"Avoidance of Creatine Kinase-MB (CK-MB) Testing for Non-traumatic Chest Pain",ECPR45,Registry/QCDR,Process,Y,77.89 - 91.34,91.33 - 96.96,96.95 - 97.15,97.14 - 98.18,98.17 - 99.08,99.07 - 99.34,99.33 - 99.58,<= 99.57,No
"Appropriate management of anticoagulation in the peri-procedural period rate - EGD",GIQIC10,Registry/QCDR,Process,Y,23.33 - 53.34,53.33 - 72.80,72.79 - 86.16,86.15 - 94.70,94.69 - 97.74,97.73 - 99.99,--,100.00,No
"Appropriate indication for colonoscopy",GIQIC12,Registry/QCDR,Process,Y,76.2 - 83.68,83.67 - 86.45,86.44 - 89.32,89.31 - 91.06,91.05 - 92.89,92.88 - 94.53,94.52 - 96.32,<= 96.31,No
"Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients",GIQIC15,Registry/QCDR,Process,Y,54.24 - 64.59,64.58 - 73.09,73.08 - 78.96,78.95 - 82.62,82.61 - 85.49,85.48 - 88.01,88.0 - 91.24,<= 91.23,No
"Appropriate follow-up interval of 5 years for colonoscopies with findings of sessile serrated polyps < 10 mm without dysplasia",GIQIC17,Registry/QCDR,Process,Y,71.23 - 80.01,80.0 - 84.63,84.62 - 86.37,86.36 - 90.49,90.48 - 93.76,93.75 - 95.66,95.65 - 97.51,<= 97.5,No
"Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm",GIQIC18,Registry/QCDR,Process,Y,83.13 - 89.30,89.29 - 92.32,92.31 - 95.01,95.0 - 97.11,97.1 - 97.93,97.92 - 99.25,99.24 - 99.99,100.00,No
"Appropriate indication for esophagogastroduodenoscopy (EGD)",GIQIC19,Registry/QCDR,Process,Y,26.88 - 34.14,34.13 - 41.87,41.86 - 49.12,49.11 - 60.11,60.1 - 68.37,68.36 - 83.58,83.57 - 92.86,<= 92.85,No
"Appropriate follow-up interval of 10 years for colonoscopies with only hyperplastic polyp findings",GIQIC20,Registry/QCDR,Process,Y,25.0 - 70.91,70.9 - 80.55,80.54 - 86.85,86.84 - 91.31,91.3 - 95.19,95.18 - 96.98,96.97 - 99.99,100.00,No
"Hypogonadism: Serum T, CBC, PSA, IPSS within 6  months of Rx",IQSS1,Registry/QCDR,Process,Y,1.09 - 1.60,1.59 - 2.64,2.63 - 3.04,3.03 - 3.71,3.7 - 5.42,5.41 - 6.26,6.25 - 8.34,<= 8.33,No
"Prostate Cancer: Newly diagnosed with documented T stage, PSA score, and Gleason score",IQSS2,Registry/QCDR,Process,Y,1.21 - 2.26,2.25 - 3.07,3.06 - 3.69,3.68 - 4.77,4.76 - 5.01,5.0 - 8.53,8.52 - 12.65,<= 12.64,No
"Prostate Cancer: Treatment Options Counseling",IQSS3,Registry/QCDR,Process,Y,56.0 - 68.74,68.73 - 75.91,75.9 - 80.61,80.6 - 84.01,84.0 - 90.92,90.91 - 93.27,93.26 - 95.79,<= 95.78,No
"BPH: Anticholinergics",IQSS4,Registry/QCDR,Process,Y,25.76 - 39.59,39.58 - 52.39,52.38 - 60.01,60.0 - 64.01,64.0 - 68.01,68.0 - 72.74,72.73 - 79.56,<= 79.55,No
"Endothelial Keratoplasty - Post-operative improvement in best corrected visual acuity to 20/40 or better",IRIS1,Registry/QCDR,Outcome,Y,9.52 - 22.74,22.73 - 32.09,32.08 - 37.05,37.04 - 50.73,50.72 - 53.98,53.97 - 58.01,58.0 - 75.01,<= 75.0,No
"Exudative Age-Related Macular Degeneration - Loss of Visual Acuity",IRIS10,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,No
"Nonexudative Age-Related Macular Degeneration - Loss of Visual Acuity",IRIS11,Registry/QCDR,Outcome,Y,80.13 - 86.22,86.21 - 88.81,88.8 - 90.71,90.7 - 92.56,92.55 - 93.95,93.94 - 95.31,95.3 - 96.56,<= 96.55,No
"Diabetic Macular Edema - Loss of Visual Acuity",IRIS13,Registry/QCDR,Outcome,Y,73.68 - 79.36,79.35 - 83.34,83.33 - 86.95,86.94 - 89.19,89.18 - 90.49,90.48 - 91.85,91.84 - 93.76,<= 93.75,No
"Acute Anterior Uveitis - Post-treatment visual acuity",IRIS16,Registry/QCDR,Outcome,Y,86.67 - 91.31,91.3 - 93.84,93.83 - 95.25,95.24 - 95.99,95.98 - 96.98,96.97 - 98.51,98.5 - 99.99,100.00,No
"Acute Anterior Uveitis - Post-treatment Grade 0 anterior chamber cells",IRIS17,Registry/QCDR,Outcome,Y,19.23 - 32.15,32.14 - 46.33,46.32 - 55.01,55.0 - 63.34,63.33 - 69.58,69.57 - 74.33,74.32 - 81.83,<= 81.82,No
"Glaucoma - Intraocular Pressure (IOP) Reduction",IRIS2,Registry/QCDR,IntermediateOutcome,Y,51.59 - 69.79,69.78 - 78.80,78.79 - 84.66,84.65 - 88.90,88.89 - 91.54,91.53 - 93.60,93.59 - 95.33,<= 95.32,Yes
"Refractive Surgery:  Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better",IRIS23,Registry/QCDR,Outcome,Y,19.02 - 45.91,45.9 - 55.01,55.0 - 65.23,65.22 - 75.50,75.49 - 81.59,81.58 - 87.70,87.69 - 94.88,<= 94.87,No
"Adenoviral Conjunctivitis:  Avoidance of Antibiotics",IRIS25,Registry/QCDR,Efficiency,Y,37.5 - 16.68,16.67 - 7.15,7.14 - 2.79,2.78 - 0.01,--,--,--,0.00,No
"Intravitreal Injections: Avoidance of Routine Antibiotic Use",IRIS26,Registry/QCDR,Efficiency,Y,5.45 - 3.04,3.03 - 1.58,1.57 - 0.61,0.6 - 0.01,--,--,--,0.00,No
"Complications After Cataract Surgery",IRIS27,Registry/QCDR,Outcome,Y,1.57 - 0.65,0.64 - 0.22,0.21 - 0.01,--,--,--,--,0.00,No
"Regaining Vision After Cataract Surgery",IRIS28,Registry/QCDR,Outcome,Y,20.61 - 31.08,31.07 - 38.00,37.99 - 44.66,44.65 - 51.06,51.05 - 56.73,56.72 - 62.67,62.66 - 69.79,<= 69.78,No
"Improved visual acuity after epiretinal membrane treatment within 90 days",IRIS29,Registry/QCDR,Outcome,Y,15.38 - 19.62,19.61 - 20.84,20.83 - 27.79,27.78 - 31.59,31.58 - 32.92,32.91 - 34.39,34.38 - 50.01,<= 50.0,No
"Glaucoma - Visual Field Progression",IRIS3,Registry/QCDR,Outcome,Y,20.67 - 17.15,17.14 - 14.40,14.39 - 12.01,12.0 - 9.20,9.19 - 7.15,7.14 - 5.33,5.32 - 4.01,<= 4.0,No
"Return to OR within 90 days after epiretinal membrane surgical treatment",IRIS30,Registry/QCDR,Outcome,Y,1.2 - 0.01,--,--,--,--,--,--,0.00,No
"Avoidance of Genetic Testing for Age-related Macular Degeneration",IRIS31,Registry/QCDR,Efficiency,Y,--,--,--,--,--,--,--,0.00,No
"Return to OR within 90 days after macular hole surgery",IRIS33,Registry/QCDR,Outcome,Y,5.26 - 2.03,2.02 - 0.01,--,--,--,--,--,0.00,No
"Age-Related Macular Degeneration: Disease Progression",IRIS34,Registry/QCDR,Outcome,Y,6.52 - 4.30,4.29 - 2.89,2.88 - 1.86,1.85 - 0.78,0.77 - 0.01,--,--,0.00,No
"Glaucoma - Intraocular Pressure Reduction Following Laser Trabeculoplasty",IRIS4,Registry/QCDR,Outcome,Y,13.48 - 18.26,18.25 - 23.82,23.81 - 27.28,27.27 - 31.00,30.99 - 34.95,34.94 - 39.03,39.02 - 43.34,<= 43.33,No
"Amblyopia - Interocular Visual Acuity",IRIS7,Registry/QCDR,Outcome,Y,16.13 - 20.84,20.83 - 26.93,26.92 - 29.81,29.8 - 32.15,32.14 - 33.34,33.33 - 35.20,35.19 - 37.21,<= 37.2,No
"Diabetic Retinopathy - Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy",IRIS9,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,No
"M2S 1: Procedures with statin and antiplatelet agents prescribed at discharge",M2S1,Registry/QCDR,Process,Y,62.16 - 71.44,71.43 - 77.51,77.5 - 80.96,80.95 - 82.99,82.98 - 86.01,86.0 - 86.37,86.36 - 88.90,<= 88.89,No
"Case Delay",MA1,Registry/QCDR,Efficiency,Y,12.16 - 9.63,9.62 - 6.78,6.77 - 4.38,4.37 - 3.18,3.17 - 2.35,2.34 - 1.12,1.11 - 0.49,<= 0.48,No
"Risk standardized rate of patients who experienced a postoperative escalation in care event following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation",MBSAQIP10,Registry/QCDR,Outcome,Y,8.45 - 7.90,7.89 - 6.91,6.9 - 5.01,5.0 - 3.94,3.93 - 3.09,3.08 - 2.18,2.17 - 1.62,<= 1.61,No
"Risk standardized rate of patients who experienced a pulmonary complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy",MBSAQIP11,Registry/QCDR,Outcome,Y,2.63 - 1.91,1.9 - 1.42,1.41 - 1.01,1.0 - 0.25,0.24 - 0.01,--,--,0.00,No
"Risk standardized rate of patients who experienced a postoperative complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation",MBSAQIP12,Registry/QCDR,Outcome,Y,4.0 - 3.34,3.33 - 2.51,2.5 - 2.28,2.27 - 1.46,1.45 - 1.10,1.09 - 0.98,0.97 - 0.01,0.00,No
"Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation",MBSAQIP7,Registry/QCDR,Outcome,Y,2.74 - 2.31,2.3 - 2.18,2.17 - 1.55,1.54 - 0.69,0.68 - 0.48,0.47 - 0.01,--,0.00,Yes
"Risk standardized rate of patients who experienced an extended length of stay (> 3 days) following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation",MBSAQIP8,Registry/QCDR,Outcome,Y,5.0 - 3.34,3.33 - 2.83,2.82 - 1.92,1.91 - 1.56,1.55 - 1.16,1.15 - 1.06,1.05 - 0.49,<= 0.48,Yes
"Heel Pain Treatment Outcomes for Adults",MEX1,Registry/QCDR,Outcome,Y,2.26 - 12.01,12.0 - 23.91,23.9 - 37.30,37.29 - 46.82,46.81 - 57.26,57.25 - 66.11,66.1 - 75.01,<= 75.0,No
"Bunion Outcome - Adult and Adolescent",MEX4,Registry/QCDR,Outcome,Y,1.96 - 4.04,4.03 - 6.84,6.83 - 12.47,12.46 - 18.89,18.88 - 23.48,23.47 - 31.23,31.22 - 41.81,<= 41.8,No
"Hammer Toe Outcome",MEX5,Registry/QCDR,Outcome,Y,1.69 - 2.87,2.86 - 7.90,7.89 - 10.35,10.34 - 15.39,15.38 - 18.61,18.6 - 27.28,27.27 - 45.72,<= 45.71,No
"Rate of witnessed gastric aspiration",MIRAMED17,Registry/QCDR,Outcome,Y,0.41 - 0.27,0.26 - 0.17,0.16 - 0.13,0.12 - 0.11,0.1 - 0.09,0.08 - 0.07,0.06 - 0.03,<= 0.02,No
"Unplanned Conversion to General Anesthesia from Regional or MAC for all scheduled cases",MIRAMED18,Registry/QCDR,Process,Y,96.78 - 98.20,98.19 - 98.38,98.37 - 98.97,98.96 - 99.31,99.3 - 99.73,99.72 - 99.84,99.83 - 99.94,<= 99.93,No
"Onset atrial fibrillation or dysrhythmia requiring unanticipated therapy",MIRAMED19,Registry/QCDR,Outcome,Y,0.47 - 0.31,0.3 - 0.20,0.19 - 0.15,0.14 - 0.12,0.11 - 0.10,0.09 - 0.09,0.08 - 0.05,<= 0.04,No
"Medicare Spending Per Beneficiary (MSPB)",MSPB_1,AdministrativeClaims,,Y,43284.0 - 24418.01,24418.0 - 23155.01,23155.0 - 22358.01,22358.0 - 21726.01,21726.0 - 21180.01,21180.0 - 20670.01,20670.0 - 20136.01,<= 20136.0,No
"Prostate Biopsy Antibiotic Compliance",MUSIC1,Registry/QCDR,Process,Y,99.35 - 99.99,--,--,--,--,--,--,100.00,Yes
"Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months",MUSIC11,Registry/QCDR,Process,Y,4.55 - 5.14,5.13 - 7.70,7.69 - 9.53,9.52 - 12.38,12.37 - 16.01,16.0 - 20.08,20.07 - 26.10,<= 26.09,No
"Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation",NHCR4,Registry/QCDR,Process,Y,7.69 - 16.01,16.0 - 20.90,20.89 - 29.52,29.51 - 39.30,39.29 - 50.01,50.0 - 63.42,63.41 - 74.92,<= 74.91,No
"AVOIDING EXCESSIVE USE OF EPIDURAL INJECTIONS IN MANAGING CHRONIC PAIN ORIGINATING IN THE CERVICAL AND THORACIC SPINE",NIPM8,Registry/QCDR,Efficiency,Y,99.2 - 99.62,99.61 - 99.99,--,--,--,--,--,100.00,No
"AVOIDING EXCESSIVE USE OF THERAPEUTIC FACET JOINT INTERVENTIONS IN MANAGING CHRONIC CERVICAL AND THORACIC SPINAL PAIN",NIPM9,Registry/QCDR,Efficiency,Y,--,--,--,--,--,--,--,100.00,No
"Unplanned Admission to Hospital Following Percutaneous Spine Procedure within the 30-Day Post-procedure Period",NPAGSC9,Registry/QCDR,Outcome,Y,28.15 - 19.32,19.31 - 2.71,2.7 - 0.01,--,--,--,--,0.00,No
"Advance Care Planning in Stage 4 Disease",PIMSH1,Registry/QCDR,PatientEngagementExperience,Y,0.65 - 1.41,1.4 - 2.81,2.8 - 9.02,9.01 - 20.97,20.96 - 34.32,34.31 - 43.45,43.44 - 58.34,<= 58.33,No
"Utilization of GCSF in Metastatic Colon Cancer",PIMSH2,Registry/QCDR,Process,Y,57.14 - 36.06,36.05 - 30.44,30.43 - 27.51,27.5 - 24.15,24.14 - 22.01,22.0 - 16.91,16.9 - 13.44,<= 13.43,No
"Central Line Ultrasound Guidance",QUANTUM31,Registry/QCDR,Process,Y,55.26 - 78.56,78.55 - 92.77,92.76 - 95.37,95.36 - 98.46,98.45 - 99.32,99.31 - 99.99,--,100.00,No
"Upper Extremity Edema Improvement",RCOIR10,Registry/QCDR,Outcome,Y,36.62 - 48.20,48.19 - 52.28,52.27 - 56.64,56.63 - 60.94,60.93 - 67.75,67.74 - 73.09,73.08 - 75.01,<= 75.0,No
"Improved Access Site Bleeding",RCOIR7,Registry/QCDR,Outcome,Y,48.28 - 53.74,53.73 - 62.68,62.67 - 68.19,68.18 - 73.47,73.46 - 75.77,75.76 - 83.20,83.19 - 86.43,<= 86.42,No
"Post Procedure Bleeding",RCOIR8,Registry/QCDR,Outcome,Y,0.3 - 0.25,0.24 - 0.20,0.19 - 0.12,0.11 - 0.09,0.08 - 0.01,--,--,0.00,No
"Hospitalization Rate Following Procedures Performed under Procedure Sedation Analgesia",RPAQIR11,Registry/QCDR,Outcome,Y,0.77 - 0.48,0.47 - 0.37,0.36 - 0.24,0.23 - 0.18,0.17 - 0.13,0.12 - 0.01,--,0.00,Yes
"Arterial Complication Rate Following Arteriovenous Access Intervention",RPAQIR12,Registry/QCDR,Outcome,Y,0.81 - 0.48,0.47 - 0.38,0.37 - 0.25,0.24 - 0.17,0.16 - 0.12,0.11 - 0.07,0.06 - 0.01,0.00,Yes
"Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician",RPAQIR13,Registry/QCDR,Process,Y,69.09 - 75.38,75.37 - 79.20,79.19 - 82.23,82.22 - 83.81,83.8 - 85.08,85.07 - 87.95,87.94 - 89.04,<= 89.03,Yes
"Prolonged Length of Stay Following Coronary Artery Bypass Grafting",STS1,Registry/QCDR,Outcome,Y,9.3 - 7.70,7.69 - 5.98,5.97 - 4.65,4.64 - 3.71,3.7 - 3.34,3.33 - 2.36,2.35 - 1.83,<= 1.82,No
"Prolonged Length of Stay for Coronary Artery Bypass Grafting (CABG) + Valve Replacement",STS3,Registry/QCDR,Outcome,Y,13.64 - 10.72,10.71 - 10.01,10.0 - 8.34,8.33 - 7.61,7.6 - 5.14,5.13 - 4.56,4.55 - 3.46,<= 3.45,Yes
"Prolonged Length of Stay following Valve Surgery",STS5,Registry/QCDR,Outcome,Y,12.3 - 9.03,9.02 - 7.07,7.06 - 6.62,6.61 - 5.12,5.11 - 3.74,3.73 - 2.85,2.84 - 2.00,<= 1.99,No
"Patient Centered Surgical Risk Assessment and Communication for Cardiac Surgery",STS7,Registry/QCDR,Process,Y,1.96 - 3.58,3.57 - 12.89,12.88 - 34.77,34.76 - 56.53,56.52 - 77.49,77.48 - 89.30,89.29 - 96.47,<= 96.46,No
"Total Per Capita Costs (TPCC)",TPCC_1,AdministrativeClaims,,Y,79929.9 - 18838.76,18838.75 - 15754.41,15754.4 - 14355.01,14355.0 - 13447.81,13447.8 - 12712.16,12712.15 - 11998.91,11998.9 - 11197.01,<= 11197.0,No
"Controlled Gout for Patients on Urate-Lowering Pharmacologic Therapy",UREQA3,Registry/QCDR,IntermediateOutcome,Y,45.1 - 55.25,55.24 - 57.95,57.94 - 62.77,62.76 - 65.23,65.22 - 66.43,66.42 - 67.87,67.86 - 71.20,<= 71.19,No
"Folic or Folinic Acid Therapy for Patients Treated with Methotrexate",UREQA4,Registry/QCDR,Process,Y,69.77 - 78.11,78.1 - 85.35,85.34 - 90.59,90.58 - 93.31,93.3 - 94.32,94.31 - 94.98,94.97 - 96.84,<= 96.83,No
"UR006 - Regular Evaluation of Psoriatic Arthritis (PsA)",UREQA5,Registry/QCDR,Process,Y,6.17 - 7.77,7.76 - 10.35,10.34 - 12.14,12.13 - 15.16,15.15 - 17.88,17.87 - 24.37,24.36 - 28.26,<= 28.25,No